BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology. 2002;122:1609-1619. [PMID: 12016426 DOI: 10.1053/gast.2002.33411] [Cited by in Crossref: 374] [Cited by in F6Publishing: 363] [Article Influence: 18.7] [Reference Citation Analysis]
Number Citing Articles
1 Jiang X, Li H, Qiao H, Jiang H, Xu R, Sun X. Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice. Cancer Sci 2009;100:2226-33. [PMID: 19709125 DOI: 10.1111/j.1349-7006.2009.01306.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
2 Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Masaki T, Fukui H. Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression. J Hepatol. 2005;42:687-693. [PMID: 15826718 DOI: 10.1016/j.jhep.2004.12.025] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 2.4] [Reference Citation Analysis]
3 Xu L, Li L, Wang P, Zhang M, Zhang Y, Hao X, Yan L, Li B, Wen T, Xu M. Novel Prognostic Nomograms for Hepatocellular Carcinoma Patients with Microvascular Invasion: Experience from a Single Center. Gut Liver 2019;13:669-82. [PMID: 30970430 DOI: 10.5009/gnl18489] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
4 Yang TB, Yi F, Liu WF, Yang YH, Yang C, Sun J. Identification of hsa_circ_0039053 as an up-regulated and oncogenic circRNA in hepatocellular carcinoma via the miR-637-mediated USP21 activation. J Cancer 2020;11:6950-9. [PMID: 33123285 DOI: 10.7150/jca.48998] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zhong JH, Ke Y, Gong WF, Xiang BD, Ma L, Ye XP, Peng T, Xie GS, Li LQ. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg. 2014;260:329-340. [PMID: 24096763 DOI: 10.1097/sla.0000000000000236] [Cited by in Crossref: 215] [Cited by in F6Publishing: 144] [Article Influence: 30.7] [Reference Citation Analysis]
6 Pompili M, Riccardi L, Covino M, Barbaro B, Di Stasi C, Orefice R, Gasbarrini G, Rapaccini GL. Contrast-enhanced gray-scale harmonic ultrasound in the efficacy assessment of ablation treatments for hepatocellular carcinoma. Liver Int. 2005;25:954-961. [PMID: 16162152 DOI: 10.1111/j.1478-3231.2005.01135.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
7 Ellebrecht DB, Theisen-Kunde D, Kuempers C, Keck T, Kleemann M, Wolken H. Analysis of laparoscopic laser liver resection in standardized porcine model. Surg Endosc 2018;32:4966-72. [PMID: 29869079 DOI: 10.1007/s00464-018-6258-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
8 Altomonte J, Braren R, Schulz S, Marozin S, Rummeny EJ, Schmid RM, Ebert O. Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats. Hepatology 2008;48:1864-73. [PMID: 19003878 DOI: 10.1002/hep.22546] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
9 Wible BC, Rilling WS, Drescher P, Hieb RA, Saeian K, Frangakis C, Chen Y, Eastwood D, Kim HS. Longitudinal quality of life assessment of patients with hepatocellular carcinoma after primary transarterial chemoembolization. J Vasc Interv Radiol. 2010;21:1024-1030. [PMID: 20621715 DOI: 10.1016/j.jvir.2010.03.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
10 Shih WL, Yu MW, Chen PJ, Yeh SH, Lo MT, Chang HC, Liaw YF, Lin SM, Liu CJ, Lee SD, Lin CL, Hsiao CK, Yang SY, Chen CJ. Localization of a susceptibility locus for hepatocellular carcinoma to chromosome 4q in a hepatitis B hyperendemic area. Oncogene 2006;25:3219-24. [PMID: 16407824 DOI: 10.1038/sj.onc.1209345] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
11 Deli A, Kreidl E, Santifaller S, Trotter B, Seir K, Berger W, Schulte-Hermann R, Rodgarkia-Dara C, Grusch M. Activins and activin antagonists in hepatocellular carcinoma. World J Gastroenterol 2008; 14(11): 1699-1709 [PMID: 18350601 DOI: 10.3748/wjg.14.1699] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 46] [Article Influence: 3.3] [Reference Citation Analysis]
12 Nagler A, Ohana M, Shibolet O, Shapira M, Alper R, Vlodavsky I, Pines M, Ilan Y. Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone. European Journal of Cancer 2004;40:1397-403. [DOI: 10.1016/j.ejca.2003.11.036] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.1] [Reference Citation Analysis]
13 Yegin EG, Siykhymbayev A, Eren F, Bekiroglu N, Ozdogan OC. Prognostic implication of serum vascular endothelial growth factor in advanced hepatocellular carcinoma staging. Annals of Hepatology 2013;12:915-25. [DOI: 10.1016/s1665-2681(19)31297-9] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
14 Yoshiji H, Noguchi R, Kuriyama S, Ikenaka Y, Yoshii J, Yanase K, Namisaki T, Kitade M, Masaki T, Fukui H. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am J Physiol Gastrointest Liver Physiol. 2005;288:G907-G913. [PMID: 15618280 DOI: 10.1152/ajpgi.00420.2004] [Cited by in Crossref: 100] [Cited by in F6Publishing: 100] [Article Influence: 5.6] [Reference Citation Analysis]
15 Cillo U, Vitale A, Navaglia F, Basso D, Montin U, Bassanello M, D'Amico F, Ciarleglio FA, Brolese A, Zanus G, De Pascale V, Plebani M, D'Amico DF. Role of blood AFP mRNA and tumor grade in the preoperative prognostic evaluation of patients with hepatocellular carcinoma. World J Gastroenterol 2005;11:6920-5. [PMID: 16437593 DOI: 10.3748/wjg.v11.i44.6920] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
16 Li J, Tan H, Dong X, Xu Z, Shi C, Han X, Jiang H, Krissansen G, Sun X. Antisense integrin αV and β3 gene therapy suppresses subcutaneously implanted hepatocellular carcinomas. Digestive and Liver Disease 2007;39:557-65. [DOI: 10.1016/j.dld.2007.01.025] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
17 Poon TC, Hui AY, Chan HL, Ang IL, Chow SM, Wong N, Sung JJ. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem. 2005;51:328-335. [PMID: 15590748 DOI: 10.1373/clinchem.2004.041764] [Cited by in Crossref: 101] [Cited by in F6Publishing: 91] [Article Influence: 5.6] [Reference Citation Analysis]
18 Choi DT, Davila JA, Sansgiry S, David E, Singh H, El-Serag HB, Hsiao-Fan Sada Y. Factors Associated With Delay of Diagnosis of Hepatocellular Carcinoma in Patients With Cirrhosis. Clin Gastroenterol Hepatol 2021;19:1679-87. [PMID: 32693047 DOI: 10.1016/j.cgh.2020.07.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
19 Alves A, Mamede A, Alves M, Oliveira P, Rocha S, Botelho M, Maia C. Glycolysis Inhibition as a Strategy for Hepatocellular Carcinoma Treatment? CCDT 2018;19:26-40. [DOI: 10.2174/1568009618666180430144441] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
20 Fecht WJ Jr, Befeler AS. Hepatocellular carcinoma: updates in primary prevention. Curr Gastroenterol Rep 2004;6:37-43. [PMID: 14720452 DOI: 10.1007/s11894-004-0024-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
21 Yao FY, Bass NM, Nikolai B, Merriman R, Davern TJ, Kerlan R, Ascher NL, Roberts JP. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: Implications for the current organ allocation policy. Liver Transpl. 2003;9:684-692. [PMID: 12827553 DOI: 10.1053/jlts.2003.50147] [Cited by in Crossref: 193] [Cited by in F6Publishing: 179] [Article Influence: 10.2] [Reference Citation Analysis]
22 Jansen MC, van Hillegersberg R, Chamuleau RA, van Delden OM, Gouma DJ, van Gulik TM. Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review. Eur J Surg Oncol. 2005;31:331-347. [PMID: 15837037 DOI: 10.1016/j.ejso.2004.10.011] [Cited by in Crossref: 93] [Cited by in F6Publishing: 84] [Article Influence: 5.5] [Reference Citation Analysis]
23 Hendricks-Wenger A, Hutchison R, Vlaisavljevich E, Allen IC. Immunological Effects of Histotripsy for Cancer Therapy. Front Oncol 2021;11:681629. [PMID: 34136405 DOI: 10.3389/fonc.2021.681629] [Reference Citation Analysis]
24 Wang Y, Jiang J, Ma H, Han J, Sun Z, Liu Z, Xu Z. Role of ZIC1 methylation in hepatocellular carcinoma and its clinical significance. Tumor Biol 2014;35:7429-33. [DOI: 10.1007/s13277-014-1971-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
25 Liu YI, Kamaya A, Jeffrey RB, Shin LK. Multidetector Computed Tomography Triphasic Evaluation of the Liver Before Transplantation: Importance of Equilibrium Phase Washout and Morphology for Characterizing Hypervascular Lesions. Journal of Computer Assisted Tomography 2012;36:213-9. [DOI: 10.1097/rct.0b013e318247c8f0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
26 Lyytinen I, Lempinen M, Nordin A, Mäkisalo H, Stenman UH, Isoniemi H. Prognostic significance of tumor-associated trypsin inhibitor (TATI) and human chorionic gonadotropin-β (hCGβ) in patients with hepatocellular carcinoma. Scand J Gastroenterol 2013;48:1066-73. [PMID: 23889187 DOI: 10.3109/00365521.2013.805810] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
27 Yin F, Cao N, Xiang X, Feng H, Li F, Li M, Xia Q, Zuo X. DNA Framework-based Topological Aptamer for Differentiating Subtypes of Hepatocellular Carcinoma Cells. Chem Res Chin Univ 2021;37:919-24. [DOI: 10.1007/s40242-021-1159-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Jin J, You H, Yu B, Deng Y, Tang N, Yao G, Shu H, Yang S, Qin W. Epigenetic inactivation of SLIT2 in human hepatocellular carcinomas. Biochem Biophys Res Commun. 2009;379:86-91. [PMID: 19100240 DOI: 10.1016/j.bbrc.2008.12.022] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
29 Choi D, Lim HK, Joh JW, Kim SJ, Kim MJ, Rhim H, Kim YS, Yoo BC, Paik SW, Park CK. Combined hepatectomy and radiofrequency ablation for multifocal hepatocellular carcinomas: long-term follow-up results and prognostic factors. Ann Surg Oncol. 2007;14:3510-3518. [PMID: 17653800 DOI: 10.1245/s10434-007-9492-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
30 Tangkijvanich P, Mahachai V, Suwangool P, Poovorawan Y. Gender difference in clinicopathologic features and survival of patients with hepatocellular carcinoma. World J Gastroenterol 2004; 10(11): 1547-1550 [PMID: 15162522 DOI: 10.3748/wjg.v10.i11.1547] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 40] [Article Influence: 2.3] [Reference Citation Analysis]
31 Vivarelli M, Guglielmi A, Ruzzenente A, Cucchetti A, Bellusci R, Cordiano C, Cavallari A. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg. 2004;240:102-107. [PMID: 15213625 DOI: 10.1097/01.sla.0000129672.51886.44] [Cited by in Crossref: 178] [Cited by in F6Publishing: 158] [Article Influence: 9.9] [Reference Citation Analysis]
32 Dong Y, Cai Q, Fu L, Liu H, Ma M, Wu X. Study of the G Protein Nucleolar 2 Value in Liver Hepatocellular Carcinoma Treatment and Prognosis. Biomed Res Int 2021;2021:4873678. [PMID: 34337013 DOI: 10.1155/2021/4873678] [Reference Citation Analysis]
33 Maddala YK, Stadheim L, Andrews JC, Burgart LJ, Rosen CB, Kremers WK, Gores G. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: Outcome with chemoembolization: Drop-Out Rates for HCC. Liver Transpl 2004;10:449-55. [DOI: 10.1002/lt.20099] [Cited by in Crossref: 168] [Cited by in F6Publishing: 152] [Article Influence: 9.3] [Reference Citation Analysis]
34 Xu Q, Lin W, Tao C, Huang X, Li J. Chondroitin polymerizing factor (CHPF) contributes to malignant proliferation and migration of hepatocellular carcinoma cells. Biochem Cell Biol 2020;98:362-9. [PMID: 32383983 DOI: 10.1139/bcb-2019-0227] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
35 Zhu R, Yang J, Xu L, Dai W, Wang F, Shen M, Zhang Y, Zhang H, Chen K, Cheng P. Diagnostic Performance of Des-γ-carboxy Prothrombin for Hepatocellular Carcinoma: A Meta-Analysis. Gastroenterol Res Pract. 2014;2014:529314. [PMID: 25165471 DOI: 10.1155/2014/529314] [Cited by in Crossref: 15] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
36 Cillo U, Bassanello M, Vitale A, Grigoletto FA, Burra P, Fagiuoli S, D'amico F, Ciarleglio FA, Boccagni P, Brolese A, Zanus G, D'amico DF. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? Journal of Hepatology 2004;40:124-31. [DOI: 10.1016/j.jhep.2003.09.027] [Cited by in Crossref: 133] [Cited by in F6Publishing: 122] [Article Influence: 7.4] [Reference Citation Analysis]
37 Wang F, Qi X, Li Z, Jin S, Xie Y, Zhong H. lncRNA CADM1-AS1 inhibits cell-cycle progression and invasion via PTEN/AKT/GSK-3β axis in hepatocellular carcinoma. Cancer Manag Res 2019;11:3813-28. [PMID: 31118799 DOI: 10.2147/CMAR.S197673] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
38 Urata Y, Kubo S, Takemura S, Uenishi T, Kodai S, Shinkawa H, Sakae M, Kaneda K, Ohata K, Nozawa A. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2012;19:685-696. [PMID: 22203455 DOI: 10.1007/s00534-011-0489-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
39 Yoshiji H. Anti-fibrotic therapy: Are matrix metalloproteinases friends or foes? Hepatol Res. 2009;39:748-750. [PMID: 19709329 DOI: 10.1111/j.1872-034x.2009.00573.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
40 Kaji K, Yoshiji H, Kitade M, Ikenaka Y, Noguchi R, Shirai Y, Yoshii J, Yanase K, Namisaki T, Yamazaki M, Tsujimoto T, Kawaratani H, Fukui H. Selective aldosterone blocker, eplerenone, attenuates hepatocellular carcinoma growth and angiogenesis in mice: SAB suppression of HCC growth. Hepatology Research 2010;40:540-9. [DOI: 10.1111/j.1872-034x.2010.00636.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
41 Leakey JE, Seng JE, Allaben WT. Body weight considerations in the B6C3F1 mouse and the use of dietary control to standardize background tumor incidence in chronic bioassays. Toxicology and Applied Pharmacology 2003;193:237-65. [DOI: 10.1016/j.taap.2003.07.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
42 Liu F, Wang P, Jiang X, Tan G, Qiao H, Jiang H, Krissansen GW, Sun X. Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma. Cancer Sci 2008;99:2055-61. [PMID: 19016766 DOI: 10.1111/j.1349-7006.2008.00905.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 28] [Article Influence: 0.4] [Reference Citation Analysis]
43 Lim ZW, Varma VB, Ramanujan RV, Miserez A. Magnetically responsive peptide coacervates for dual hyperthermia and chemotherapy treatments of liver cancer. Acta Biomaterialia 2020;110:221-30. [DOI: 10.1016/j.actbio.2020.04.024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
44 Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol. 2005;11:7391-7400. [PMID: 16437707 DOI: 10.3748/wjg.v11.i47.7391] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 94] [Article Influence: 2.3] [Reference Citation Analysis]
45 Yu HC, Cheng JS, Lai KH, Lin CP, Lo GH, Lin CK, Hsu PI, Chan HH, Lo CC, Tsai WL, Chen WC. Factors for early tumor recurrence of single small hepatocellular carcinoma after percutaneous radiofrequency ablation therapy. World J Gastroenterol 2005; 11(10): 1439-1444 [PMID: 15770718 DOI: 10.3748/wjg.v11.i10.1439] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 52] [Article Influence: 3.1] [Reference Citation Analysis]
46 Xu J, Hu S, Li S, Wang W, Wu Y, Su Z, Zhou X, Gao Y, Cheng X, Zheng Q. Systemic immune-inflammation index predicts postoperative acute kidney injury in hepatocellular carcinoma patients after hepatectomy. Medicine (Baltimore) 2021;100:e25335. [PMID: 33832108 DOI: 10.1097/MD.0000000000025335] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Fields AC, Cotsonis G, Sexton D, Santoianni R, Cohen C. Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome. Mod Pathol. 2004;17:1378-1385. [PMID: 15195112 DOI: 10.1038/modpathol.3800203] [Cited by in Crossref: 71] [Cited by in F6Publishing: 59] [Article Influence: 4.2] [Reference Citation Analysis]
48 Zhang CG, Zhu QL, Zhou Y, Liu Y, Chen WL, Yuan ZQ, Yang SD, Zhou XF, Zhu AJ, Zhang XN, Jin Y. N-Succinyl-chitosan nanoparticles coupled with low-density lipoprotein for targeted osthole-loaded delivery to low-density lipoprotein receptor-rich tumors. Int J Nanomedicine 2014;9:2919-32. [PMID: 24966673 DOI: 10.2147/IJN.S59799] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
49 Li X, Cheng T, He Y, Zhou S, Wang Y, Zhang K, Yu P. High glucose regulates ERp29 in hepatocellular carcinoma by LncRNA MEG3-miRNA 483-3p pathway. Life Sci. 2019;232:116602. [PMID: 31251997 DOI: 10.1016/j.lfs.2019.116602] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
50 Mazzoccoli G, Tarquini R, Valoriani A, Oben J, Vinciguerra M, Marra F. Management strategies for hepatocellular carcinoma: old certainties and new realities. Clin Exp Med 2016;16:243-56. [PMID: 26077653 DOI: 10.1007/s10238-015-0368-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
51 Zhao Y, Chen J, Wei W, Qi X, Li C, Ren J. The dual-inhibitory effect of miR-338-5p on the multidrug resistance and cell growth of hepatocellular carcinoma. Signal Transduct Target Ther 2018;3:3. [PMID: 29527329 DOI: 10.1038/s41392-017-0003-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
52 Abdo AA, Hassanain M, AlJumah A, Al Olayan A, Sanai FM, Alsuhaibani HA, Abdulkareem H, Abdallah K, AlMuaikeel M, Al Saghier M, Babatin M, Kabbani M, Bazarbashi S, Metrakos P, Bruix J; Saudi Association for the Study of Liver Diseases and Transplantation., Saudi Oncology Society. Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. Ann Saudi Med 2012;32:174-99. [PMID: 22366832 DOI: 10.5144/0256-4947.2012.174] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
53 Yang X, Liu H, Sun CK, Natarajan A, Hu X, Wang X, Allegretta M, Guttmann RD, Gambhir SS, Chua MS, Cheng Z, So SK. Imaging of hepatocellular carcinoma patient-derived xenografts using ⁸⁹Zr-labeled anti-glypican-3 monoclonal antibody. Biomaterials 2014;35:6964-71. [PMID: 24836949 DOI: 10.1016/j.biomaterials.2014.04.089] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
54 Scherber PR, Gäbelein G, Eisele RM, Igna D, Glanemann M. [Early stage liver cancer : Hepatocellular carcinoma]. Chirurg 2018;89:281-8. [PMID: 29075797 DOI: 10.1007/s00104-017-0538-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
55 Pandey P, Rahman M, Bhatt PC, Beg S, Paul B, Hafeez A, Al-abbasi FA, Nadeem MS, Baothman O, Anwar F, Kumar V. Implication of nano-antioxidant therapy for treatment of hepatocellular carcinoma using PLGA nanoparticles of rutin. Nanomedicine 2018;13:849-70. [DOI: 10.2217/nnm-2017-0306] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 12.5] [Reference Citation Analysis]
56 Kow AWC. Transplantation vs liver resection in patients with hepatocellular carcinoma. Transl Gastroenterol Hepatol. 2019;4:33. [PMID: 31231700 DOI: 10.21037/tgh.2019.05.06] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
57 Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, Hung CH, Chen CH, Changchien CS, Hsu HC, Hu TH. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer. 2010;46:744-751. [PMID: 20060710 DOI: 10.1016/j.ejca.2009.12.018] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 5.6] [Reference Citation Analysis]
58 Ho CM, Lee PH, Chen CL, Ho MC, Wu YM, Hu RH. Long-term outcomes after resection versus transplantation for hepatocellular carcinoma within UCSF criteria. Ann Surg Oncol. 2012;19:826-833. [PMID: 21879276 DOI: 10.1245/s10434-011-1975-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
59 Guan M, Zhou Y, Zhu QL, Liu Y, Bei YY, Zhang XN, Zhang Q. N-trimethyl chitosan nanoparticle-encapsulated lactosyl-norcantharidin for liver cancer therapy with high targeting efficacy. Nanomedicine 2012;8:1172-81. [PMID: 22321383 DOI: 10.1016/j.nano.2012.01.009] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 5.3] [Reference Citation Analysis]
60 Basciano CA, Kleinstreuer C, Kennedy AS, Dezarn WA, Childress E. Computer modeling of controlled microsphere release and targeting in a representative hepatic artery system. Ann Biomed Eng 2010;38:1862-79. [PMID: 20162358 DOI: 10.1007/s10439-010-9955-z] [Cited by in Crossref: 58] [Cited by in F6Publishing: 44] [Article Influence: 4.8] [Reference Citation Analysis]
61 Ohmoto K, Yoshioka N, Tomiyama Y, Shibata N, Kawase T, Yoshida K, Kuboki M, Yamamoto S. Comparison of therapeutic effects between radiofrequency ablation and percutaneous microwave coagulation therapy for small hepatocellular carcinomas. Journal of Gastroenterology and Hepatology 2009;24:223-7. [DOI: 10.1111/j.1440-1746.2008.05596.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 5.5] [Reference Citation Analysis]
62 Friedman SL. Liver fibrosis -- from bench to bedside. J Hepatol. 2003;38 Suppl 1:S38-S53. [PMID: 12591185 DOI: 10.1016/s0168-8278(02)00429-4] [Cited by in Crossref: 1077] [Cited by in F6Publishing: 451] [Article Influence: 56.7] [Reference Citation Analysis]
63 Bishayee A, Dhir N. Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: Inhibition of cell proliferation and induction of apoptosis. Chemico-Biological Interactions 2009;179:131-44. [DOI: 10.1016/j.cbi.2008.11.015] [Cited by in Crossref: 110] [Cited by in F6Publishing: 103] [Article Influence: 8.5] [Reference Citation Analysis]
64 Harada N, Shimada M, Okano S, Suehiro T, Soejima Y, Tomita Y, Maehara Y. IL-12 gene therapy is an effective therapeutic strategy for hepatocellular carcinoma in immunosuppressed mice. J Immunol 2004;173:6635-44. [PMID: 15557154 DOI: 10.4049/jimmunol.173.11.6635] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 2.6] [Reference Citation Analysis]
65 Ethun CG, Maithel SK. Determination of Resectability. Surg Clin North Am 2016;96:163-81. [PMID: 27017857 DOI: 10.1016/j.suc.2015.12.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
66 Lodewyks C, Rodriguez JF, Yan J, Lerner B, Sun D, Rempel JD, Uhanova J, Labine M, Minuk GY. Activation of β-adrenergic receptors increases the in vitro migration of malignant hepatocytes. Hepatol Res 2011;41:1000-8. [PMID: 21951873 DOI: 10.1111/j.1872-034X.2011.00854.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
67 Varshosaz J, Farzan M. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma. World J Gastroenterol 2015; 21(42): 12022-12041 [PMID: 26576089 DOI: 10.3748/wjg.v21.i42.12022] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
68 Hourmand-Ollivier I, Chiche L. [Treatment of hepatocellular carcinoma in the cirrhotic liver]. J Chir (Paris) 2004;141:71-83. [PMID: 15133430 DOI: 10.1016/s0021-7697(04)95574-3] [Reference Citation Analysis]
69 Kaibori M, Matsui K, Ishizaki M, Saito T, Kitade H, Matsui Y, Kwon AH. Hepatic resection for hepatocellular carcinoma in the elderly. J Surg Oncol. 2009;99:154-160. [PMID: 19123236 DOI: 10.1002/jso.21221] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 4.2] [Reference Citation Analysis]
70 Guo Y, Chen Y, Ito H, Watanabe A, Ge X, Kodama T, Aburatani H. Identification and characterization of lin-28 homolog B (LIN28B) in human hepatocellular carcinoma. Gene. 2006;384:51-61. [PMID: 16971064 DOI: 10.1016/j.gene.2006.07.011] [Cited by in Crossref: 202] [Cited by in F6Publishing: 203] [Article Influence: 12.6] [Reference Citation Analysis]
71 Sun JH, Wang LG, Bao HW, Lou JL, Cai LX, Wu C, Chen LM, Zheng SS. Usefulness of C-arm angiographic computed tomography for detecting iodized oil retention during transcatheter arterial chemoembolization of hepatocellular carcinoma. J Int Med Res 2010;38:1259-65. [PMID: 20925998 DOI: 10.1177/147323001003800407] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
72 Hanje AJ, Yao FY. Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation. Curr Opin Organ Transplant 2008;13:234-40. [PMID: 18685309 DOI: 10.1097/MOT.0b013e3282fc2633] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
73 Yoo H, Kim JH, Ko GY, Kim KW, Gwon DI, Lee SG, Hwang S. Sequential transcatheter arterial chemoembolization and portal vein embolization versus portal vein embolization only before major hepatectomy for patients with hepatocellular carcinoma. Ann Surg Oncol. 2011;18:1251-1257. [PMID: 21069467 DOI: 10.1245/s10434-010-1423-3] [Cited by in Crossref: 69] [Cited by in F6Publishing: 69] [Article Influence: 5.8] [Reference Citation Analysis]
74 Alba E, Valls C, Dominguez J, Martinez L, Escalante E, Lladó L, Serrano T. Transcatheter arterial chemoembolization in patients with hepatocellular carcinoma on the waiting list for orthotopic liver transplantation. AJR Am J Roentgenol. 2008;190:1341-1348. [PMID: 18430853 DOI: 10.2214/ajr.07.2972] [Cited by in Crossref: 50] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
75 Coban S, Yüksel O, Köklü S, Ceyhan K, Baykara M, Dökmeci A. Atypical presentation of hepatocellular carcinoma: a mass on the left thoracic wall. BMC Cancer 2004;4:89. [PMID: 15574203 DOI: 10.1186/1471-2407-4-89] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
76 Rossi M, Merli M, Lai Q, Gentili F, Mennini G, Bussotti A, Pugliese F, Della Pietra F, Poli L, Novelli G, Giusto M, Ginanni Corradini S, Iappelli M, Onetti Muda A, Di Tondo U, Gossetti F, Attili A, Berloco P. Outcome After Liver Transplantation in Patients With Cirrhosis and Hepatocellular Carcinoma. Transplantation Proceedings 2007;39:1895-7. [DOI: 10.1016/j.transproceed.2007.05.083] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
77 Kaibori M, Ishizaki M, Matsui K, Kwon AH. Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma. J Surg Oncol. 2010;102:462-468. [PMID: 20872949 DOI: 10.1002/jso.21631] [Cited by in Crossref: 91] [Cited by in F6Publishing: 89] [Article Influence: 7.6] [Reference Citation Analysis]
78 Hussein RH, Khalifa FK. The protective role of ellagitannins flavonoids pretreatment against N-nitrosodiethylamine induced-hepatocellular carcinoma. Saudi J Biol Sci 2014;21:589-96. [PMID: 25473368 DOI: 10.1016/j.sjbs.2014.03.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
79 Yao S, Wei Y, Ye Z, Chen J, Duan T, Zhang Z, Song B. Hepatic Steatosis Has No Effect in Diagnosis Accuracy of LI-RADS v2018 Categorization of Hepatocellular Carcinoma in MR Imaging. J Magn Reson Imaging 2021. [PMID: 34121266 DOI: 10.1002/jmri.27783] [Reference Citation Analysis]
80 Jeon T, Ko MJ, Seo YR, Jung SJ, Seo D, Park SY, Park KU, Kim KS, Kim M, Seo JH, Park IC, Kim MJ, Bae JH, Song DK, Cho CH, Lee JH, Lee YH. Silencing CDCA8 Suppresses Hepatocellular Carcinoma Growth and Stemness via Restoration of ATF3 Tumor Suppressor and Inactivation of AKT/β-Catenin Signaling. Cancers (Basel) 2021;13:1055. [PMID: 33801424 DOI: 10.3390/cancers13051055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Kang YK. Expression of Multidrug Resistance Protein 1 in Human Hepatocellular Carcinoma. Korean J Pathol 2011;45:281. [DOI: 10.4132/koreanjpathol.2011.45.3.281] [Reference Citation Analysis]
82 Wei S, Hao X, Zhan D, Xiong M, Li K, Chen X, Huang Z. Are surgical indications of Barcelona Clinic Liver Cancer staging classification justified? J Huazhong Univ Sci Technolog Med Sci. 2011;31:637-641. [PMID: 22038353 DOI: 10.1007/s11596-011-0574-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
83 Chen J, Wu G, Li Y. Evaluation of Serum Des-Gamma-Carboxy Prothrombin for the Diagnosis of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Meta-Analysis. Dis Markers. 2018;2018:8906023. [PMID: 30402170 DOI: 10.1155/2018/8906023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
84 Maeda T, Hong J, Konishi K, Nakatsuji T, Yasunaga T, Yamashita Y, Taketomi A, Kotoh K, Enjoji M, Nakashima H, Tanoue K, Maehara Y, Hashizume M. Tumor ablation therapy of liver cancers with an open magnetic resonance imaging-based navigation system. Surg Endosc 2009;23:1048-53. [PMID: 18813998 DOI: 10.1007/s00464-008-0123-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
85 Shim JH, Park J, Nam BH, Lee WJ, Kim C. Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 2009;63:459-67. [DOI: 10.1007/s00280-008-0759-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
86 Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Uemura M, Masaki T, Fukui H. Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice. Gut 2005;54:1768-75. [PMID: 16033879 DOI: 10.1136/gut.2005.067900] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
87 Wang L, Levin MS. Suppression of FGF signaling: A putative mechanism for the chemopreventive effects of acyclic retinoid in hepatocellular carcinoma. Gastroenterology 2005;128:228-31. [DOI: 10.1053/j.gastro.2004.11.047] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
88 Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Yanase K, Namisaki T, Kitade M, Yamazaki M, Tsujinoue H, Masaki T, Fukui H. Involvement of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma development. Journal of Hepatology 2004;41:97-103. [DOI: 10.1016/j.jhep.2004.03.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
89 Nagae G, Ido K, Isoda N, Sato S, Kita H, Sugano K. LAPAROSCOPIC ABLATION THERAPY FOR HEPATOCELLULAR CARCINOMA. Dig Endosc 2005;17:1-8. [DOI: 10.1111/j.1443-1661.2005.00471.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
90 Guglielmi A, Ruzzenente A, Pachera S, Valdegamberi A, Sandri M, D’Onofrio M, Iacono C. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol. 2008;103:597-604. [PMID: 17970836 DOI: 10.1111/j.1572-0241.2007.01604.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 4.7] [Reference Citation Analysis]
91 Chen CT, Tseng YC, Yang CW, Lin HH, Chen PJ, Huang TY, Shih YL, Chang WK, Hsieh TY, Chu HC. Increased Risks of Spontaneous Bacterial Peritonitis and Interstitial Lung Disease in Primary Biliary Cirrhosis Patients With Concomitant Sjögren Syndrome. Medicine (Baltimore). 2016;95:e2537. [PMID: 26765478 DOI: 10.1097/md.0000000000002537] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
92 Zhao WC, Zhang HB, Yang N, Fu Y, Qian W, Chen BD, Fan LF, Yang GS. Preoperative predictors of short-term survival after hepatectomy for multinodular hepatocellular carcinoma. World J Gastroenterol 2012; 18(25): 3272-3281 [PMID: 22783052 DOI: 10.3748/wjg.v18.i25.3272] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
93 Ng KK, Vauthey J, Pawlik TM, Lauwers GY, Regimbeau J, Belghiti J, Ikai I, Yamaoka Y, Curley SA, Nagorney DM, Ng IO, Fan ST, Poon RT. Is Hepatic Resection for Large or Multinodular Hepatocellular Carcinoma Justified? Results From a Multi-Institutional Database. Ann Surg Oncol 2005;12:364-73. [DOI: 10.1245/aso.2005.06.004] [Cited by in Crossref: 167] [Cited by in F6Publishing: 81] [Article Influence: 9.8] [Reference Citation Analysis]
94 Spangenberg HC, Thimme R, Blum HE. Advances in prevention and diagnosis of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2008;2:425-33. [PMID: 19072390 DOI: 10.1586/17474124.2.3.425] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
95 Nakano K, Iwamoto Y, Takata W, Matsumoto Y, Ueoka R. Specific accumulation and growth inhibitory effects of hybrid liposomes to hepatoma cells in vitro. Bioorg Med Chem Lett 2002;12:3251-4. [PMID: 12392725 DOI: 10.1016/s0960-894x(02)00723-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
96 Yuan RH, Jeng YM, Hu RH, Lai PL, Lee PH, Cheng CC, Hsu HC. Role of p53 and β-catenin mutations in conjunction with CK19 expression on early tumor recurrence and prognosis of hepatocellular carcinoma. J Gastrointest Surg. 2011;15:321-329. [PMID: 21061181 DOI: 10.1007/s11605-010-1373-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
97 Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, Comunale MA, D'Amelio A, Lok AS, Block TM. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol. 2005;43:1007-1012. [PMID: 16137783 DOI: 10.1016/j.jhep.2005.05.028] [Cited by in Crossref: 234] [Cited by in F6Publishing: 224] [Article Influence: 13.8] [Reference Citation Analysis]
98 Mehdizadeh A, Somi MH, Darabi M, Jabbarpour-bonyadi M. Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma. Mol Biol Rep 2016;43:107-16. [DOI: 10.1007/s11033-016-3943-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
99 Imura S, Teraoku H, Yoshikawa M, Ishikawa D, Yamada S, Saito Y, Iwahashi S, Ikemoto T, Morine Y, Shimada M. Potential predictive factors for microvascular invasion in hepatocellular carcinoma classified within the Milan criteria. Int J Clin Oncol 2018;23:98-103. [PMID: 28875240 DOI: 10.1007/s10147-017-1189-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
100 Jin H, Yu M, Lin Y, Hou B, Wu Z, Li Z, Sun J. MiR-502-3P suppresses cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting SET. Onco Targets Ther 2016;9:3281-9. [PMID: 27330307 DOI: 10.2147/OTT.S87183] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
101 Zollner G, Wagner M, Fickert P, Silbert D, Fuchsbichler A, Zatloukal K, Denk H, Trauner M. Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int. 2005;25:367-379. [PMID: 15780063 DOI: 10.1111/j.1478-3231.2005.01033.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 84] [Article Influence: 5.5] [Reference Citation Analysis]
102 Qiu G, Lin Y, Zhang H, Wu D. miR-139-5p inhibits epithelial-mesenchymal transition, migration and invasion of hepatocellular carcinoma cells by targeting ZEB1 and ZEB2. Biochem Biophys Res Commun 2015;463:315-21. [PMID: 26022123 DOI: 10.1016/j.bbrc.2015.05.062] [Cited by in Crossref: 57] [Cited by in F6Publishing: 62] [Article Influence: 8.1] [Reference Citation Analysis]
103 Yuan RH, Chang KT, Chen YL, Hsu HC, Lee PH, Lai PL, Jeng YM. S100P expression is a novel prognostic factor in hepatocellular carcinoma and predicts survival in patients with high tumor stage or early recurrent tumors. PLoS One. 2013;8:e65501. [PMID: 23785431 DOI: 10.1371/journal.pone.0065501] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
104 Yan S, Shan X, Chen K, Liu Y, Yu G, Chen Q, Zeng T, Zhu L, Dang H, Chen F, Ling J, Huang A, Tang H. LINC00052/miR-101-3p axis inhibits cell proliferation and metastasis by targeting SOX9 in hepatocellular carcinoma. Gene 2018;679:138-49. [PMID: 30098428 DOI: 10.1016/j.gene.2018.08.038] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
105 Yusuf H, Fahriani M, Murzalina C, Mawaddah RD. Inhibitory effects on HepG2 cell proliferation and induction of cell cycle arrest by Chromolaena odorata leaf extract and fractions. PHAR 2022;69:377-84. [DOI: 10.3897/pharmacia.69.e80498] [Reference Citation Analysis]
106 Chen H, Miao J, Li H, Wang C, Li J, Zhu Y, Wang J, Wu X, Qiao H. Expression and prognostic significance of p21-activated kinase 6 in hepatocellular carcinoma. J Surg Res. 2014;189:81-88. [PMID: 24576777 DOI: 10.1016/j.jss.2014.01.049] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
107 Guo Y, Zhao J, Bi J, Wu Q, Wang X, Lai Q. Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early hepatocellular carcinoma in patients with cirrhosis. J Hematol Oncol 2012;5:37. [PMID: 22760167 DOI: 10.1186/1756-8722-5-37] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
108 Bialecki ES, Di Bisceglie AM. Clinical presentation and natural course of hepatocellular carcinoma: . European Journal of Gastroenterology & Hepatology 2005;17:485-9. [DOI: 10.1097/00042737-200505000-00003] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
109 Nanashima A, Sumida Y, Morino S, Yamaguchi H, Tanaka K, Shibasaki S, Ide N, Sawai T, Yasutake T, Nakagoe T. The Japanese integrated staging score using liver damage grade for hepatocellular carcinoma in patients after hepatectomy. Eur J Surg Oncol. 2004;30:765-770. [PMID: 15296991 DOI: 10.1016/j.ejso.2004.05.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
110 Baccarani U, Isola M, Adani GL, Benzoni E, Avellini C, Lorenzin D, Bresadola F, Uzzau A, Risaliti A, Beltrami AP, Soldano F, De Anna D, Bresadola V. Superiority of transplantation versus resection for the treatment of small hepatocellular carcinoma. Transplant Int 2008;21:247-54. [DOI: 10.1111/j.1432-2277.2007.00597.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
111 Han Z, Feng W, Hu R, Ge Q, Ma W, Zhang W, Xu S, Zhan B, Zhang L, Sun X, Zhou X. RNA-seq profiling reveals PBMC RNA as a potential biomarker for hepatocellular carcinoma. Sci Rep 2021;11:17797. [PMID: 34493740 DOI: 10.1038/s41598-021-96952-x] [Reference Citation Analysis]
112 Reynaert H, Rombouts K, Vandermonde A, Urbain D, Kumar U, Bioulac-Sage P, Pinzani M, Rosenbaum J, Geerts A. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut. 2004;53:1180-1189. [PMID: 15247189 DOI: 10.1136/gut.2003.036053] [Cited by in Crossref: 73] [Cited by in F6Publishing: 73] [Article Influence: 4.1] [Reference Citation Analysis]
113 Lin ZZ, Jeng YM, Hu FC, Pan HW, Tsao HW, Lai PL, Lee PH, Cheng AL, Hsu HC. Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC. BMC Cancer. 2010;10:461. [PMID: 20799978 DOI: 10.1186/1471-2407-10-461] [Cited by in Crossref: 61] [Cited by in F6Publishing: 71] [Article Influence: 5.1] [Reference Citation Analysis]
114 Trevisani F, Cantarini MC, Labate AM, De Notariis S, Rapaccini G, Farinati F, Del Poggio P, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Bernardi M; Italian Liver Cancer (ITALICA) group. Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol. 2004;99:1470-1476. [PMID: 15307862 DOI: 10.1111/j.1572-0241.2004.30137.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 80] [Article Influence: 5.0] [Reference Citation Analysis]
115 Filmus J, Capurro M. Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn. 2004;8:207-212. [PMID: 15887976 DOI: 10.1007/bf03260065] [Cited by in Crossref: 54] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
116 Baccarani U, Benzoni E, Adani G, Avellini C, Lorenzin D, Sainz-barriga M, Bresadola V, Uzzau A, Risaliti A, Beltrami C, Bresadola F. Superiority of Transplantation Versus Resection for the Treatment of Small Hepatocellular Carcinoma. Transplantation Proceedings 2007;39:1898-900. [DOI: 10.1016/j.transproceed.2007.05.045] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
117 Damjanovska S, Davitkov P, Gopal S, Kostadinova L, Kowal C, Lange A, Moreland A, Shive CL, Wilson B, Bej T, Al-Kindi S, Falck-Ytter Y, Zidar DA, Anthony DD. High Red Cell Distribution Width and Low Absolute Lymphocyte Count Associate With Subsequent Mortality in HCV Infection. Pathog Immun 2021;6:90-104. [PMID: 34988340 DOI: 10.20411/pai.v6i2.467] [Reference Citation Analysis]
118 Shen Y, Bu L, Li R, Chen Z, Tian F, Ge Q. Expression And Biological Interaction Network Of RHOC For Hepatic Carcinoma With Metastasis In PBMC Samples. Onco Targets Ther 2019;12:9117-28. [PMID: 31806997 DOI: 10.2147/OTT.S222235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
119 Vongchan P, Wutti-In Y, Sajomsang W, Gonil P, Kothan S, Linhardt RJ. N,N,N-Trimethyl chitosan nanoparticles for the delivery of monoclonal antibodies against hepatocellular carcinoma cells. Carbohydr Polym 2011;85:215-20. [PMID: 21552341 DOI: 10.1016/j.carbpol.2011.02.018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
120 Yoshiji H, Noguchi R, Kojima H, Ikenaka Y, Kitade M, Kaji K, Uemura M, Yamao J, Fujimoto M, Yamazaki M, Toyohara M, Mitoro A, Fukui H. Interferon augments the anti-fibrotic activity of an angiotensin-converting enzyme inhibitor in patients with refractory chronic hepatitis C. World J Gastroenterol 2006; 12(42): 6786-6791 [PMID: 17106926 DOI: 10.3748/wjg.v12.i42.6786] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
121 Aqel BA, Ho SB. Surveillance for hepatocellular carcinoma. Postgrad Med 2006;119:19-24. [PMID: 17128641 DOI: 10.1080/00325481.2006.11446046] [Reference Citation Analysis]
122 El-Bendary M, Elalfy H, Zalata K. Predictors of hepatocyte proliferative activity in chronic hepatitis B and C vs. steatohepatitis as assessed by the monoclonal antibody MIB1-Ki-67. Arab J Gastroenterol 2011;12:119-24. [PMID: 22055588 DOI: 10.1016/j.ajg.2011.07.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
123 Jeong KY, Lee EJ, Kim SJ, Yang SH, Sung YC, Seong J. Irradiation-induced localization of IL-12-expressing mesenchymal stem cells to enhance the curative effect in murine metastatic hepatoma. Int J Cancer 2015;137:721-30. [PMID: 25639194 DOI: 10.1002/ijc.29428] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
124 Gallegos-Orozco JF, Vargas HE. Liver transplantation: from Child to MELD. Med Clin North Am. 2009;93:931-950, ix. [PMID: 19577123 DOI: 10.1016/j.mcna.2009.03.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
125 Zhou Y, Sun K, Ma Y, Yang H, Zhang Y, Kong X, Wei L. Autophagy inhibits chemotherapy-induced apoptosis through downregulating Bad and Bim in hepatocellular carcinoma cells. Sci Rep 2014;4:5382. [PMID: 24947039 DOI: 10.1038/srep05382] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
126 Liu Z, Yang L, Xu J, Zhang X, Wang B. Enhanced expression and clinical significance of chemokine receptor CXCR2 in hepatocellular carcinoma. J Surg Res. 2011;166:241-246. [PMID: 20018298 DOI: 10.1016/j.jss.2009.07.014] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
127 Yuan RH, Jeng YM, Chen HL, Lai PL, Pan HW, Hsieh FJ, Lin CY, Lee PH, Hsu HC. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol. 2006;209:549-558. [PMID: 16739096 DOI: 10.1002/path.2011] [Cited by in Crossref: 105] [Cited by in F6Publishing: 111] [Article Influence: 6.6] [Reference Citation Analysis]
128 Shih YL, Hsieh CB, Lai HC, Yan MD, Hsieh TY, Chao YC, Lin YW. SFRP1 suppressed hepatoma cells growth through Wnt canonical signaling pathway. Int J Cancer. 2007;121:1028-1035. [PMID: 17443492 DOI: 10.1002/ijc.22750] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 4.3] [Reference Citation Analysis]
129 Lu C, Qiu J, Huang P, Zou R, Hong J, Li B, Chen G, Yuan Y. NADPH oxidase DUOX1 and DUOX2 but not NOX4 are independent predictors in hepatocellular carcinoma after hepatectomy. Tumor Biol 2011;32:1173-82. [DOI: 10.1007/s13277-011-0220-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
130 Kung J, Macdougall M, Madhavan K, Garden O, Parks R. Predicting survival in patients with hepatocellular carcinoma: A UK perspective. European Journal of Surgical Oncology (EJSO) 2007;33:188-94. [DOI: 10.1016/j.ejso.2006.10.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
131 Sunagozaka H, Honda M, Yamashita T, Nishino R, Takatori H, Arai K, Yamashita T, Sakai Y, Kaneko S. Identification of a secretory protein c19orf10 activated in hepatocellular carcinoma. Int J Cancer 2011;129:1576-85. [PMID: 21128247 DOI: 10.1002/ijc.25830] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
132 Chuma M, Hige S, Kamiyama T, Meguro T, Nagasaka A, Nakanishi K, Yamamoto Y, Nakanishi M, Kohara T, Sho T, Yamamoto K, Horimoto H, Kobayashi T, Yokoo H, Matsushita M, Todo S, Asaka M. The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol. 2009;44:991-999. [PMID: 19554391 DOI: 10.1007/s00535-009-0093-z] [Cited by in Crossref: 75] [Cited by in F6Publishing: 77] [Article Influence: 5.8] [Reference Citation Analysis]
133 De Carlis L, Di Sandro S, Giacomoni A, Mangoni I, Lauterio A, Mihaylov P, Cusumano C, Rampoldi A. Liver Transplantation for Hepatocellular Carcinoma Recurrence After Liver Resection: Why Deny This Chance of Cure? Journal of Clinical Gastroenterology 2013;47:352-8. [DOI: 10.1097/mcg.0b013e31826e6caf] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
134 Muela Molinero A, Ballesteros del Río B, Nistal de Paz F, Jorquera Plaza F. [Hepatocellular carcinoma producing syndrome of inappropriate antidiuretic hormone secretion]. Med Clin (Barc) 2003;121:396. [PMID: 14565918 DOI: 10.1016/s0025-7753(03)73959-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
135 Chiba T, Kamiya A, Yokosuka O, Iwama A. Cancer stem cells in hepatocellular carcinoma: Recent progress and perspective. Cancer Lett. 2009;286:145-153. [PMID: 19464789 DOI: 10.1016/j.canlet.2009.04.027] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 4.2] [Reference Citation Analysis]
136 Qi X, Ng KT, Lian QZ, Liu XB, Li CX, Geng W, Ling CC, Ma YY, Yeung WH, Tu WW, Fan ST, Lo CM, Man K. Clinical significance and therapeutic value of glutathione peroxidase 3 (GPx3) in hepatocellular carcinoma. Oncotarget 2014;5:11103-20. [PMID: 25333265 DOI: 10.18632/oncotarget.2549] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
137 Chan HH, Chu TH, Chien HF, Sun CK, Wang EM, Pan HB, Kuo HM, Hu TH, Lai KH, Cheng JT, Tai MH. Rapid induction of orthotopic hepatocellular carcinoma in immune-competent rats by non-invasive ultrasound-guided cells implantation. BMC Gastroenterol 2010;10:83. [PMID: 20649994 DOI: 10.1186/1471-230X-10-83] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
138 Sun B, Zheng CS, Feng GS, Wang Y, Xia XW, Kan XF. Radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: a meta-analysis. Shijie Huaren Xiaohua Zazhi 2011; 19(31): 3255-3263 [DOI: 10.11569/wcjd.v19.i31.3255] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
139 Ronot M, Asselah T, Paradis V, Michoux N, Dorvillius M, Baron G, Marcellin P, Van Beers BE, Vilgrain V. Liver fibrosis in chronic hepatitis C virus infection: differentiating minimal from intermediate fibrosis with perfusion CT. Radiology. 2010;256:135-142. [PMID: 20574090 DOI: 10.1148/radiol.10091295] [Cited by in Crossref: 97] [Cited by in F6Publishing: 88] [Article Influence: 8.1] [Reference Citation Analysis]
140 Yamanaka J, Okada T, Saito S, Kondo Y, Yoshida Y, Suzumura K, Hirano T, Iimuro Y, Fujimoto J. Minimally invasive laparoscopic liver resection: 3D MDCT simulation for preoperative planning. J Hepatobiliary Pancreat Surg. 2009;16:808-815. [PMID: 19466379 DOI: 10.1007/s00534-009-0112-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
141 Dai T, Zhang D, Cai M, Wang C, Wu Z, Ying Z, Wu J, Li M, Xie D, Li J. Golgi phosphoprotein 3 (GOLPH3) promotes hepatocellular carcinoma cell aggressiveness by activating the NF-κB pathway. J Pathol. 2015;235:490-501. [PMID: 25385148 DOI: 10.1002/path.4479] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
142 Ballem N, Berber E, Pitt T, Siperstein A. Laparoscopic radiofrequency ablation of unresectable hepatocellular carcinoma: long-term follow-up. HPB (Oxford) 2008;10:315-20. [PMID: 18982145 DOI: 10.1080/13651820802247102] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
143 Kolarević D, Tomasević Z, Boricić I, Rasić DM, Dekić NA, Milovanović Z, Jelić S. Metastasis of hepatocellular carcinoma presented as a tumor of the maxillary sinus and retrobulbar tumor. Vojnosanit Pregl 2011;68:359-62. [PMID: 21627021 DOI: 10.2298/vsp1104359k] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
144 Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012;39:410-433. [PMID: 22846859 DOI: 10.1053/j.seminoncol.2012.05.001] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 10.3] [Reference Citation Analysis]
145 Marrero JA, Hussain HK, Nghiem HV, Umar R, Fontana RJ, Lok AS. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl. 2005;11:281-289. [PMID: 15719410 DOI: 10.1002/lt.20357] [Cited by in Crossref: 169] [Cited by in F6Publishing: 142] [Article Influence: 9.9] [Reference Citation Analysis]
146 Ziada DH, El Sadany S, Soliman H, Abd-Elsalam S, Salama M, Hawash N, Selim A, Hamisa M, Elsabagh HM. Prevalence of hepatocellular carcinoma in chronic hepatitis C patients in Mid Delta, Egypt: A single center study. J Egypt Natl Canc Inst 2016;28:257-62. [PMID: 27378258 DOI: 10.1016/j.jnci.2016.06.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
147 Ito K, Arai M, Imazeki F, Yonemitsu Y, Bekku D, Kanda T, Fujiwara K, Fukai K, Sato K, Itoga S. Risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Scand J Gastroenterol. 2010;45:243-249. [PMID: 20095888 DOI: 10.3109/00365520903450113] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
148 Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, Neri D, Boccagni P, Srsen N, D'amico F, Ciarleglio FA, Bridda A, Francesco D'amico D. Prospective validation of the Barcelona Clinic Liver Cancer staging system. Journal of Hepatology 2006;44:723-31. [DOI: 10.1016/j.jhep.2005.12.015] [Cited by in Crossref: 275] [Cited by in F6Publishing: 259] [Article Influence: 17.2] [Reference Citation Analysis]
149 Lin ZZ, Hsu C, Hu FC, Shao YY, Chang DY, Yang CH, Hong RL, Hsu CH, Cheng AL. Factors impacting prognosis prediction in BCLC stage C and Child-Pugh class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy. Oncologist. 2012;17:970-977. [PMID: 22673633 DOI: 10.1634/theoncologist.2011-0411] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
150 Mackenna DA, Montag A, Boyer SH, Linemeyer DL, Erion MD. Delivery of high levels of anti-proliferative nucleoside triphosphates to CYP3A-expressing cells as a potential treatment for hepatocellular carcinoma. Cancer Chemother Pharmacol 2009;64:981-91. [DOI: 10.1007/s00280-009-0953-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
151 Corona-Villalobos CP, Halappa VG, Geschwind JF, Bonekamp S, Reyes D, Cosgrove D, Pawlik TM, Kamel IR. Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib. Eur Radiol. 2015;25:380-390. [PMID: 25226843 DOI: 10.1007/s00330-014-3412-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
152 Ahmed S, Johnson PT, Fishman EK. Defining vascular signatures of malignant hepatic masses: role of MDCT with 3D rendering. Abdom Imaging 2013;38:763-73. [DOI: 10.1007/s00261-012-9934-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
153 Zhao L, Mou DC, Peng JR, Huang L, Wu ZA, Leng XS. Diagnostic value of cancer-testis antigen mRNA in peripheral blood from hepatocellular carcinoma patients. World J Gastroenterol 2010; 16(32): 4072-4078 [PMID: 20731022 DOI: 10.3748/wjg.v16.i32.4072] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
154 Ettorre GM, Levi Sandri GB, Colasanti M, Mascianà G, de Werra E, Santoro R, Lepiane P, Montalbano M, Antonini M, Vennarecci G. Liver resection for hepatocellular carcinoma ≥5 cm. Transl Gastroenterol Hepatol 2017;2:22. [PMID: 28447057 DOI: 10.21037/tgh.2017.03.13] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
155 Cai X, Yu L, Chen Z, Ye F, Ren Z, Jin P. Arsenic trioxide-induced upregulation of miR-1294 suppresses tumor growth in hepatocellular carcinoma by targeting TEAD1 and PIM1. Cancer Biomark 2020;28:221-30. [PMID: 32280078 DOI: 10.3233/CBM-190490] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
156 Toyoda H, Kumada T, Tada T, Niinomi T, Ito T, Kaneoka Y, Maeda A. Prognostic significance of a combination of pre- and post-treatment tumor markers for hepatocellular carcinoma curatively treated with hepatectomy. J Hepatol. 2012;57:1251-1257. [PMID: 22824818 DOI: 10.1016/j.jhep.2012.07.018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
157 Yuan R, Lai H, Hsu H, Lai P, Jeng Y. Expression of Bile Duct Transcription Factor HNF1β Predicts Early Tumor Recurrence and Is a Stage-Independent Prognostic Factor in Hepatocellular Carcinoma. J Gastrointest Surg 2014;18:1784-94. [DOI: 10.1007/s11605-014-2596-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
158 Weeks SM, Burke C. Local therapeutic treatments for focal liver disease. Radiol Clin North Am 2005;43:899-914, viii. [PMID: 16098346 DOI: 10.1016/j.rcl.2005.05.003] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
159 Li H, Wolfe A, Septer S, Edwards G, Zhong X, Abdulkarim AB, Ranganathan S, Apte U. Deregulation of Hippo kinase signalling in human hepatic malignancies. Liver Int. 2012;32:38-47. [PMID: 22098159 DOI: 10.1111/j.1478-3231.2011.02646.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 87] [Article Influence: 8.0] [Reference Citation Analysis]
160 Zhang L, Liu H, Sun L, Li N, Ding H, Zheng J. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study. Acta Histochem. 2012;114:547-552. [PMID: 22119409 DOI: 10.1016/j.acthis.2011.10.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
161 Cheng W, Huang PC, Chao HM, Jeng YM, Hsu HC, Pan HW, Hwu WL, Lee YM. Glypican-3 induces oncogenicity by preventing IGF-1R degradation, a process that can be blocked by Grb10. Oncotarget 2017;8:80429-42. [PMID: 29113314 DOI: 10.18632/oncotarget.19035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
162 Sankaran S, Adaikkalam A, Rajan SS, Devi R, Subramanian P. Influence of circadian rhythms in tumorigenesis – Role of vanillic acid on liver cancer. Biological Rhythm Research 2020;51:294-300. [DOI: 10.1080/09291016.2018.1528682] [Reference Citation Analysis]
163 Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. Journal of Hepatology 2003;38:136-49. [DOI: 10.1016/s0168-8278(02)00432-4] [Cited by in Crossref: 156] [Cited by in F6Publishing: 56] [Article Influence: 8.2] [Reference Citation Analysis]
164 Nandi S, Chandra S, Sikder R, Bhattacharya S, Ahir M, Biswal D, Adhikary A, Pramanik NR, Lai TK, Drew MGB, Acharya K. Characterization and Inception of a Triterpenoid Astrakurkurol, as a Cytotoxic Molecule on Human Hepatocellular Carcinoma Cells, Hep3B. J Agric Food Chem 2019;67:7660-73. [DOI: 10.1021/acs.jafc.9b01203] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
165 Taha MM, Abdul AB, Abdullah R, Ibrahim TA, Abdelwahab SI, Mohan S. Potential chemoprevention of diethylnitrosamine-initiated and 2-acetylaminofluorene-promoted hepatocarcinogenesis by zerumbone from the rhizomes of the subtropical ginger (Zingiber zerumbet). Chem Biol Interact. 2010;186:295-305. [PMID: 20452335 DOI: 10.1016/j.cbi.2010.04.029] [Cited by in Crossref: 76] [Cited by in F6Publishing: 66] [Article Influence: 6.3] [Reference Citation Analysis]
166 Ueno S, Sakoda M, Kubo F, Hiwatashi K, Tateno T, Baba Y, Hasegawa S, Tsubouchi H;  Kagoshima Liver Cancer Study Group. Surgical resection vs radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria. J Hepatobiliary Pancreat Surg. 2009;16:359-366. [PMID: 19300896 DOI: 10.1007/s00534-009-0069-7] [Cited by in Crossref: 89] [Cited by in F6Publishing: 86] [Article Influence: 6.8] [Reference Citation Analysis]
167 Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T. Impact of the branched-chain amino acid to tyrosine ratio and branched-chain amino acid granule therapy in patients with hepatocellular carcinoma: A propensity score analysis: BTR and BCAA in HCC patients. J Gastroenterol Hepatol 2015;30:1412-9. [DOI: 10.1111/jgh.12954] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
168 Chang L, Li C, Guo T, Wang H, Ma W, Yuan Y, Liu Q, Ye Q, Liu Z. The human RNA surveillance factor UPF1 regulates tumorigenesis by targeting Smad7 in hepatocellular carcinoma. J Exp Clin Cancer Res 2016;35:8. [PMID: 26759305 DOI: 10.1186/s13046-016-0286-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 5.5] [Reference Citation Analysis]
169 Changchien CS, Chen CL, Yen YH, Wang JH, Hu TH, Lee CM, Wang CC, Cheng YF, Huang YJ, Lin CY. Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. J Gastroenterol. 2008;43:159-170. [PMID: 18306990 DOI: 10.1007/s00535-007-2134-9] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 3.2] [Reference Citation Analysis]
170 El Moety AAA, El Moety HA. Evaluation of nitric oxide as a novel diagnostic marker for hepatocellular carcinoma. Alexandria Journal of Medicine 2011;47:31-5. [DOI: 10.1016/j.ajme.2011.04.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
171 Pascual S, Zapater P, Such J, Garcia-herola A, Sempere L, Irurzun J, Palazon JM, Carnicer F, Perez-mateo M. Comparison of staging systems to predict survival in hepatocellular carcinoma. Liver Int 2006;26:673-9. [DOI: 10.1111/j.1478-3231.2006.01282.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
172 Cheng W, Tseng CJ, Lin TT, Cheng I, Pan HW, Hsu HC, Lee YM. Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway. Carcinogenesis. 2008;29:1319-1326. [PMID: 18413366 DOI: 10.1093/carcin/bgn091] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 4.4] [Reference Citation Analysis]
173 Nishida T, Kato M, Yoshio T, Akasaka T, Yoshioka T, Michida T, Yamamoto M, Hayashi S, Hayashi Y, Tsujii M, Takehara T. Endoscopic submucosal dissection in early gastric cancer in elderly patients and comorbid conditions. World J Gastrointest Endosc 2015; 7(5): 524-531 [PMID: 25992191 DOI: 10.4253/wjge.v7.i5.524] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
174 Stone MJ, Fulmer JM, Klintmalm GB. Transplantation for Primary Hepatic Malignancy. Transplantation of the Liver. Elsevier; 2005. pp. 211-31. [DOI: 10.1016/b978-0-7216-0118-2.50020-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
175 Li HL, Ji WB, Zhao R, Duan WD, Chen YW, Wang XQ, Yu Q, Luo Y, Dong JH. Poor prognosis for hepatocellular carcinoma with transarterial chemoembolization pre-transplantation: Retrospective analysis. World J Gastroenterol 2015; 21(12): 3599-3606 [PMID: 25834326 DOI: 10.3748/wjg.v21.i12.3599] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
176 Li B, Liu H, Shang HW, Li P, Li N, Ding HG. Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients. Afr Health Sci. 2013;13:703-709. [PMID: 24250310 DOI: 10.4314/ahs.v13i3.26] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
177 Wang Q, Pan LH, Lin L, Zhang R, Du YC, Chen H, Huang M, Guo KW, Yang XZ. Essential Oil from Carpesium abrotanoides L. Induces Apoptosis via Activating Mitochondrial Pathway in Hepatocellular Carcinoma Cells. Curr Med Sci 2018;38:1045-53. [PMID: 30536068 DOI: 10.1007/s11596-018-1982-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
178 Kurtovic J, Riordan SM, Williams R. Liver transplantation for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2005;19:147-160. [PMID: 15757810 DOI: 10.1016/j.bpg.2004.10.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
179 Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004;10:S115-S120. [PMID: 14762851 DOI: 10.1002/lt.20034] [Cited by in Crossref: 459] [Cited by in F6Publishing: 424] [Article Influence: 25.5] [Reference Citation Analysis]
180 VoPham T, Bertrand KA, Hart JE, Laden F, Brooks MM, Yuan JM, Talbott EO, Ruddell D, Chang CH, Weissfeld JL. Pesticide exposure and liver cancer: a review. Cancer Causes Control 2017;28:177-90. [PMID: 28194594 DOI: 10.1007/s10552-017-0854-6] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
181 Pinzani M, Rombouts K. Liver fibrosis: from the bench to clinical targets. Digestive and Liver Disease 2004;36:231-42. [DOI: 10.1016/j.dld.2004.01.003] [Cited by in Crossref: 220] [Cited by in F6Publishing: 207] [Article Influence: 12.2] [Reference Citation Analysis]
182 Befeler AS. Chemoembolization and bland embolization: a critical appraisal. Clin Liver Dis 2005;9:287-300, vii. [PMID: 15831274 DOI: 10.1016/j.cld.2004.12.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
183 Kayar Y, Turkdogan KA, Baysal B, Unver N, Danalioglu A, Senturk H. EUS-guided FNA of a portal vein thrombus in hepatocellular carcinoma. Pan Afr Med J 2015;21:86. [PMID: 26491529 DOI: 10.11604/pamj.2015.21.86.6991] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
184 Gracia-Sancho J, Maeso-Díaz R, Fernández-Iglesias A, Navarro-Zornoza M, Bosch J. New cellular and molecular targets for the treatment of portal hypertension. Hepatol Int. 2015;9:183-191. [PMID: 25788198 DOI: 10.1007/s12072-015-9613-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
185 Chen K, Gao Q, Zhang W, Liu Z, Cai J, Liu Y, Xu J, Li J, Yang Y, Xu X. Musashi1 regulates survival of hepatoma cell lines by activation of Wnt signalling pathway. Liver Int 2015;35:986-98. [PMID: 24444033 DOI: 10.1111/liv.12458] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
186 Chen D, Chen Y, Yan Y, Pan J, Xing W, Li Q, Zeng W. Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients. BMC Cancer 2017;17:553. [PMID: 28821282 DOI: 10.1186/s12885-017-3541-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
187 Bhardwaj N, Dormer J, Ahmad F, Strickland AD, Gravante G, West K, Dennison AR, Lloyd DM. Microwave ablation of the liver: a description of lesion evolution over time and an investigation of the heat sink effect. Pathology 2011;43:725-31. [PMID: 22027742 DOI: 10.1097/PAT.0b013e32834c356c] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
188 Chávez-López MG, Zúñiga-García V, Pérez-Carreón JI, Avalos-Fuentes A, Escobar Y, Camacho J. Eag1 channels as potential early-stage biomarkers of hepatocellular carcinoma. Biologics 2016;10:139-48. [PMID: 27703327 DOI: 10.2147/BTT.S87402] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
189 Yoon JH, Lee JM, Lee YJ, Lee KB, Han JK. Added Value of sequentially performed gadoxetic acid-enhanced liver MRI for the diagnosis of small (10-19 mm) or atypical hepatic observations at contrast-enhanced CT: A prospective comparison. J Magn Reson Imaging 2019;49:574-87. [PMID: 30102433 DOI: 10.1002/jmri.26199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
190 Mazzanti R, Giallombardo AL, Mini E, Nobili S, Neri B, Arena U, Pantaleo P, Fabbroni V, Ghilardi M, Gattai R. Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: a pilot study. Dig Liver Dis. 2004;36:278-285. [PMID: 15115341 DOI: 10.1016/j.dld.2003.12.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
191 Kulkarni K, Barcak E, El-Serag H, Goodgame R. The impact of immigration on the increasing incidence of hepatocellular carcinoma in the United States. Aliment Pharmacol Ther. 2004;20:445-450. [PMID: 15298639 DOI: 10.1111/j.1365-2036.2004.02090.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
192 Chiba T, Iwama A, Yokosuka O. Cancer stem cells in hepatocellular carcinoma: Therapeutic implications based on stem cell biology. Hepatol Res. 2016;46:50-57. [PMID: 26123821 DOI: 10.1111/hepr.12548] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
193 Toyoda H, Kumada T, Tada T, Sone Y, Kaneoka Y, Maeda A. Characteristics and prognosis of patients with hepatocellular carcinoma after the year 2000 in Japan. J Gastroenterol Hepatol 2011;26:1765-71. [PMID: 21615793 DOI: 10.1111/j.1440-1746.2011.06789.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
194 Ishikawa H, Nakao K, Matsumoto K, Ichikawa T, Hamasaki K, Nakata K, Eguchi K. Antiangiogenic gene therapy for hepatocellular carcinoma using angiostatin gene. Hepatology. 2003;37:696-704. [PMID: 12601367 DOI: 10.1053/jhep.2003.50077] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
195 Koschny R, Schmidt J, Ganten TM. Beyond Milan criteria--chances and risks of expanding transplantation criteria for HCC patients with liver cirrhosis. Clin Transplant 2009;23 Suppl 21:49-60. [PMID: 19930317 DOI: 10.1111/j.1399-0012.2009.01110.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
196 Cillo U, Navaglia F, Vitale A, Molari A, Basso D, Bassanello M, Brolese A, Zanus G, Montin U, D'amico F, Ciarleglio FA, Carraro A, Bridda A, Burra P, Carraro P, Plebani M, D'amico DF. Clinical significance of alpha-fetoprotein mRNA in blood of patients with hepatocellular carcinoma. Clinica Chimica Acta 2004;347:129-38. [DOI: 10.1016/j.cccn.2004.04.032] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 1.4] [Reference Citation Analysis]
197 Piscaglia F, Bolondi L. Recent advances in the diagnosis of hepatocellular carcinoma. Hepatology Research 2007;37:S178-92. [DOI: 10.1111/j.1872-034x.2007.00183.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
198 Xie YH, He XH, Tang YT, Li JJ, Pan ZM, Qin WX, Wan DF, Gu JR. Cloning and characterization of human IC53-2, a novel CDK5 activator binding protein. Cell Res 2003;13:83-91. [PMID: 12737517 DOI: 10.1038/sj.cr.7290153] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
199 Ma L, Luo L, Qiao H, Dong X, Pan S, Jiang H, Krissansen GW, Sun X. Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy. Journal of Hepatology 2007;46:98-106. [DOI: 10.1016/j.jhep.2006.07.031] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 3.1] [Reference Citation Analysis]
200 Liu F, Tan G, Li J, Dong X, Krissansen GW, Sun X. Gene transfer of endostatin enhances the efficacy of doxorubicin to suppress human hepatocellular carcinomas in mice. Cancer Sci. 2007;98:1381-1387. [PMID: 17627616 DOI: 10.1111/j.1349-7006.2007.00542.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
201 Rampone B, Schiavone B, Confuorto G. Current management of hepatocellular cancer. Curr Oncol Rep 2010;12:186-92. [PMID: 20425078 DOI: 10.1007/s11912-010-0094-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
202 Shih YL, Hsieh CB, Yan MD, Tsao CM, Hsieh TY, Liu CH, Lin YW. Frequent concomitant epigenetic silencing of SOX1 and secreted frizzled-related proteins (SFRPs) in human hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28:551-559. [PMID: 23215838 DOI: 10.1111/jgh.12078] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
203 Elsaid NAE, Kaddah RO, Fattah MSA, Salama NM. Subtraction MRI versus diffusion weighted imaging: Which is more accurate in assessment of hepatocellular carcinoma after Trans Arterial Chemoembolization (TACE)? The Egyptian Journal of Radiology and Nuclear Medicine 2016;47:1251-64. [DOI: 10.1016/j.ejrnm.2016.07.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
204 Li T, Xie J, Shen C, Cheng D, Shi Y, Wu Z, Deng X, Chen H, Shen B, Peng C, Li H, Zhan Q, Zhu Z. Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma. Oncogene. 2016;35:1575-1584. [PMID: 26073087 DOI: 10.1038/onc.2015.223] [Cited by in Crossref: 172] [Cited by in F6Publishing: 188] [Article Influence: 24.6] [Reference Citation Analysis]
205 Asmis T, Balaa F, Scully L, Papadatos D, Marginean C, Fasih N, Shaw-Stiffel T, Goel R. Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre. Curr Oncol 2010;17:6-12. [PMID: 20404972 DOI: 10.3747/co.v17i2.555] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
206 Gores G. Hepatocellular carcinoma: Gardening strategies and bridges to transplantation. Liver Transplantation 2003;9:199-200. [DOI: 10.1053/jlts.2003.0090199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
207 de Guadalupe Chávez-López M, Pérez-Carreón JI, Zuñiga-García V, Díaz-Chávez J, Herrera LA, Caro-Sánchez CH, Acuña-Macías I, Gariglio P, Hernández-Gallegos E, Chiliquinga AJ, Camacho J. Astemizole-based anticancer therapy for hepatocellular carcinoma (HCC), and Eag1 channels as potential early-stage markers of HCC. Tumour Biol 2015;36:6149-58. [PMID: 25783527 DOI: 10.1007/s13277-015-3299-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
208 Damdinsuren B, Nagano H, Monden M. Combined intra-arterial 5-fluorouracil and subcutaneous interferon-alpha therapy for highly advanced hepatocellular carcinoma. Hepatol Res 2007;37 Suppl 2:S238-50. [PMID: 17877489 DOI: 10.1111/j.1872-034X.2007.00191.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
209 Wu JY, Cheng CC, Wang JY, Wu DC, Hsieh JS, Lee SC, Wang WM. Discovery of tumor markers for gastric cancer by proteomics. PLoS One 2014;9:e84158. [PMID: 24404153 DOI: 10.1371/journal.pone.0084158] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
210 Murray KF, Carithers RL Jr;  AASLD. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology. 2005;41:1407-1432. [PMID: 15880505 DOI: 10.1002/hep.20704] [Cited by in Crossref: 519] [Cited by in F6Publishing: 406] [Article Influence: 30.5] [Reference Citation Analysis]
211 Filmus J, Capurro M. Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn. 2004;8:207-212. [PMID: 15887976 DOI: 10.2165/00066982-200408040-00002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
212 Kang HY, Shin HD, Kim SB, Song IH. Prognosis predictability of hepatocellular carcinoma according to staging systems in hepatitis B virus-endemic area. Clin Res Hepatol Gastroenterol 2012;36:357-64. [PMID: 22326248 DOI: 10.1016/j.clinre.2011.12.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
213 Ramacciato G, Mercantini P, Petrucciani N, Ravaioli M, Cucchetti A, Del Gaudio M, Cescon M, Ziparo V, Pinna AD. Does Surgical Resection Have a Role in the Treatment of Large or Multinodular Hepatocellular Carcinoma? The American Surgeon 2010;76:1189-97. [DOI: 10.1177/000313481007601116] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
214 Dai LC, Wang X, Yao X, Min LS, Ping JL, He JF. Antisense oligonucleotides targeting midkine inhibit tumor growth in an in situ human hepatocellular carcinoma model. Acta Pharmacol Sin. 2007;28:453-458. [PMID: 17303011 DOI: 10.1111/j.1745-7254.2007.00532.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
215 Beneduce L, Castaldi F, Marino M, Tono N, Gatta A, Pontisso P, Fassina G. Improvement of liver cancer detection with simultaneous assessment of circulating levels of free alpha-fetoprotein (AFP) and AFP-IgM complexes. Int J Biol Markers 2004;19:155-9. [PMID: 15255549 DOI: 10.1177/172460080401900211] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
216 Nanashima A, Morino S, Yamaguchi H, Tanaka K, Shibasaki S, Tsuji T, Hidaka S, Sawai T, Yasutake T, Nakagoe T. Modified CLIP using PIVKA-II for evaluating prognosis after hepatectomy for hepatocellular carcinoma. European Journal of Surgical Oncology (EJSO) 2003;29:735-42. [DOI: 10.1016/j.ejso.2003.08.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
217 Ye X, Li C, Zu X, Lin M, Liu Q, Liu J, Xu G, Chen Z, Xu Y, Liu L, Luo D, Cao Z, Shi G, Feng Z, Deng H, Liao Q, Cai C, Liao DF, Wang J, Jin J, Cao D. A Large-Scale Multicenter Study Validates Aldo-Keto Reductase Family 1 Member B10 as a Prevalent Serum Marker for Detection of Hepatocellular Carcinoma. Hepatology. 2019;69:2489-2501. [PMID: 30672601 DOI: 10.1002/hep.30519] [Cited by in Crossref: 13] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
218 Blum M, Mueller C, Peck‐radosavljevic M, Wrba F, Berlakovich G, Mühlbacher F, Steiniger R, Speiser M, Pones M, Hüpfl M, Lammer J, Kettenbach J. MR‐guided percutaneous ethanol ablation of hepatocellular carcinomas before liver transplantation. Minimally Invasive Therapy & Allied Technologies 2009;16:230-40. [DOI: 10.1080/13645700701520677] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
219 Park M, Lee K, Kim H, Choi Y, Hong G, Yi N, Suh K. Primary Living-donor Liver Transplantation Is Not the Optimal Treatment Choice in Patients With Early Hepatocellular Carcinoma With Poor Tumor Biology. Transplantation Proceedings 2017;49:1103-8. [DOI: 10.1016/j.transproceed.2017.03.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
220 Wang JH, Kuo YH, Wang CC, Chen CL, Cheng YF, Hsu HC, Lu SN. Surgical resection improves the survival of selected hepatocellular carcinoma patients in Barcelona clinic liver cancer stage C. Dig Liver Dis. 2013;45:510-515. [PMID: 23218990 DOI: 10.1016/j.dld.2012.10.019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
221 Toyoda H, Kumada T, Tada T, Niinomi T, Ito T, Sone Y, Kaneoka Y, Maeda A. Non-hypervascular hypointense nodules detected by Gd-EOB-DTPA-enhanced MRI are a risk factor for recurrence of HCC after hepatectomy. J Hepatol. 2013;58:1174-1180. [PMID: 23376360 DOI: 10.1016/j.jhep.2013.01.030] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
222 Huang H, Zhang A, Cao H, Lu H, Wang B, Xie Q, Xu W, Li L. Metabolomic analyses of faeces reveals malabsorption in cirrhotic patients. Digestive and Liver Disease 2013;45:677-82. [DOI: 10.1016/j.dld.2013.01.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
223 Vossen JA, Buijs M, Syed L, Kutiyanwala F, Kutiyanwala M, Geschwind JH, Vali M. Development of a new orthotopic animal model of metastatic liver cancer in the rabbit VX2 model: effect on metastases after partial hepatectomy, intra-arterial treatment with 3-bromopyruvate and chemoembolization. Clin Exp Metastasis 2008;25:811-7. [DOI: 10.1007/s10585-008-9195-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
224 Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97. [DOI: 10.1016/s0016-5085(03)00689-9] [Cited by in Crossref: 581] [Cited by in F6Publishing: 257] [Article Influence: 30.6] [Reference Citation Analysis]
225 Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, Sun Y, Xuan SY. Association between HLA-DRB1 alleles polymorphism and hepatocellular carcinoma: a meta-analysis. BMC Gastroenterol. 2010;10:145. [PMID: 21172035 DOI: 10.1186/1471-230X-10-145.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
226 Fukami Y, Saito T, Osawa T, Arikawa T, Matsumura T, Kurahashi S, Komatsu S, Kaneko K, Sano T. Preoperative Controlling Nutritional Status plus Tumor Burden Score for the Assessment of Prognosis after Curative Liver Resection for Hepatocellular Carcinoma. Med Princ Pract 2021;30:131-7. [PMID: 33361696 DOI: 10.1159/000514031] [Reference Citation Analysis]
227 Nakahara H, Itamoto T, Katayama K, Ohdan H, Hino H, Ochi M, Tashiro H, Asahara T. Indication of Hepatectomy for Cirrhotic Patients with Hepatocellular Carcinoma Classified as Child-Pugh Class B. World J Surg 2005;29:734-8. [DOI: 10.1007/s00268-005-7750-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
228 Lin ZZ, Shau WY, Hsu C, Shao YY, Yeh YC, Kuo RN, Hsu CH, Yang JC, Cheng AL, Lai MS. Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size. PLoS One 2013;8:e80276. [PMID: 24244668 DOI: 10.1371/journal.pone.0080276] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
229 Rhu J, Kim JM, Choi GS, Kwon CHD, Joh JW. Continuing five or more locoregional therapies before living donor salvage liver transplantation for hepatocellular carcinoma is related to poor recurrence-free survival. Ann Surg Treat Res 2018;95:152-60. [PMID: 30182022 DOI: 10.4174/astr.2018.95.3.152] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
230 Ho MC, Huang GT, Tsang YM, Lee PH, Chen DS, Sheu JC, Chen CH. Liver resection improves the survival of patients with multiple hepatocellular carcinomas. Ann Surg Oncol. 2009;16:848-855. [PMID: 19159983 DOI: 10.1245/s10434-008-0282-7] [Cited by in Crossref: 78] [Cited by in F6Publishing: 80] [Article Influence: 6.0] [Reference Citation Analysis]
231 Toyoda H, Kumada T, Osaki Y, Tada T, Kaneoka Y, Maeda A. Novel method to measure serum levels of des-gamma-carboxy prothrombin for hepatocellular carcinoma in patients taking warfarin: a preliminary report. Cancer Sci 2012;103:921-5. [PMID: 22320249 DOI: 10.1111/j.1349-7006.2012.02232.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
232 Kim BK, Han KH, Park YN, Park MS, Kim KS, Choi JS, Moon BS, Chon CY, Moon YM, Ahn SH. Prediction of microvascular invasion before curative resection of hepatocellular carcinoma. J Surg Oncol. 2008;97:246-252. [PMID: 18095300 DOI: 10.1002/jso.20953] [Cited by in Crossref: 86] [Cited by in F6Publishing: 82] [Article Influence: 6.1] [Reference Citation Analysis]
233 Klein J, Dawson LA. Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. Int J Radiat Oncol Biol Phys. 2013;87:22-32. [PMID: 23219567 DOI: 10.1016/j.ijrobp.2012.08.043] [Cited by in Crossref: 115] [Cited by in F6Publishing: 103] [Article Influence: 11.5] [Reference Citation Analysis]
234 Adam R, Azoulay D, Castaing D, Eshkenazy R, Pascal G, Hashizume K, Samuel D, Bismuth H. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: A reasonable strategy? Ann Surg. 2003;238:508-18; discussion 518-9. [PMID: 14530722 DOI: 10.1097/01.sla.0000090449.87109.44] [Cited by in Crossref: 66] [Cited by in F6Publishing: 131] [Article Influence: 3.5] [Reference Citation Analysis]
235 Xiang C, Xiao Y, Ma Z, Peng Y, Li X, Mao X, Li L. Liver resection for large and huge hepatocellular carcinoma: Predictors of failure, recurrence patterns, and prognoses. Asia Pac J Clin Oncol 2022. [PMID: 35404506 DOI: 10.1111/ajco.13777] [Reference Citation Analysis]
236 Shih YL, Shyu RY, Hsieh CB, Lai HC, Liu KY, Chu TY, Lin YW. Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma. Cancer. 2006;107:579-590. [PMID: 16795071 DOI: 10.1002/cncr.22023] [Cited by in Crossref: 77] [Cited by in F6Publishing: 69] [Article Influence: 4.8] [Reference Citation Analysis]
237 Yoshiji H, Noguchi R, Yamazaki M, Ikenaka Y, Sawai M, Ishikawa M, Kawaratani H, Mashitani T, Kitade M, Kaji K, Uemura M, Yamao J, Fujimoto M, Mitoro A, Toyohara M, Yoshida M, Fukui H. Combined treatment of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates hepatic dysplastic nodule in a patient with liver cirrhosis. World J Gastroenterol 2007; 13(23): 3259-3261 [PMID: 17589909 DOI: 10.3748/wjg.v13.i23.3259] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
238 Saito S, Yamanaka J, Miura K, Nakao N, Nagao T, Sugimoto T, Hirano T, Kuroda N, Iimuro Y, Fujimoto J. A novel 3D hepatectomy simulation based on liver circulation: Application to liver resection and transplantation. Hepatology 2005;41:1297-304. [DOI: 10.1002/hep.20684] [Cited by in Crossref: 132] [Cited by in F6Publishing: 114] [Article Influence: 7.8] [Reference Citation Analysis]
239 Nanashima A, Masuda J, Miuma S, Sumida Y, Nonaka T, Tanaka K, Hidaka S, Sawai T, Nagayasu T. Selection of treatment modality for hepatocellular carcinoma according to the modified Japan Integrated Staging score. World J Gastroenterol 2008; 14(1): 58-63 [PMID: 18176962 DOI: 10.3748/wjg.14.58] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
240 Spangenberg HC, Thimme R, Blum HE. Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2009;6:423-32. [DOI: 10.1038/nrgastro.2009.86] [Cited by in Crossref: 80] [Cited by in F6Publishing: 81] [Article Influence: 6.2] [Reference Citation Analysis]
241 Testa R, Testa E, Giannini E, Botta F, Malfatti F, Chiarbonello B, Fumagalli A, Polegato S, Podesta E, Romagnoli P. Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment. Aliment Pharmacol Ther. 2003;17:1563-1569. [PMID: 12823161 DOI: 10.1046/j.1365-2036.2003.01647.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]
242 El-Baz FK, Salama A, Ali SI, Elgohary R. Haematococcus pluvialis Carotenoids Enrich Fractions Ameliorate Liver Fibrosis Induced by Thioacetamide in Rats: Modulation of Metalloproteinase and Its Inhibitor. Biomed Res Int 2021;2021:6631415. [PMID: 33628797 DOI: 10.1155/2021/6631415] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
243 Kurimoto A, Yamanaka J, Hai S, Kondo Y, Sueoka H, Ohashi K, Asano Y, Hirano T, Fujimoto J. Parenchyma-preserving hepatectomy based on portal ramification and perfusion of the right anterior section: preserving the ventral or dorsal area. J Hepatobiliary Pancreat Sci 2016;23:158-66. [DOI: 10.1002/jhbp.317] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
244 Varela M, Sala M, Llovet JM, Bruix J. Natural history and prognostic prediction of patients with hepatocellular carcinoma: REVIEW: NATURAL HISTORY AND PROGNOSTIC PREDICTION. Alimentary Pharmacology & Therapeutics 2003;17:98-102. [DOI: 10.1046/j.1365-2036.17.s2.11.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
245 Zhang ZY, Zhou ZQ, Zhou GW. Higher efficacy of antiviral therapy after major hepatectomy in patients with hepatitis B virus-related hepatocellular carcinoma of less than 3 cm. Eur J Gastroenterol Hepatol. 2014;26:1116-1124. [PMID: 25003747 DOI: 10.1097/meg.0000000000000153] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
246 Ho CM, Lee PH, Shau WY, Ho MC, Wu YM, Hu RH. Survival in patients with recurrent hepatocellular carcinoma after primary hepatectomy: comparative effectiveness of treatment modalities. Surgery. 2012;151:700-709. [PMID: 22284764 DOI: 10.1016/j.surg.2011.12.015] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 5.9] [Reference Citation Analysis]
247 Lee KK, Kim DG, Moon IS, Lee MD, Park JH. Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma. J Surg Oncol. 2010;101:47-53. [PMID: 19798686 DOI: 10.1002/jso.21415] [Cited by in Crossref: 92] [Cited by in F6Publishing: 93] [Article Influence: 7.7] [Reference Citation Analysis]
248 Murillo A, Artigas V, González JA, Gallego A, Montserrat E, Rodriguez M, Trías M. Resección hepática por hepatocarcinoma: estudio comparativo entre pacientes menores y mayores de 70 años. Cirugía Española 2013;91:224-30. [DOI: 10.1016/j.ciresp.2012.07.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
249 Tanaka H, Iwasaki Y, Nouso K, Kobayashi Y, Nakamura S, Matsumoto E, Toshikuni N, Kaneyoshi T, Ohsawa T, Takaguchi K, Fujio K, Senoh T, Ohnishi T, Sakaguchi K, Shiratori Y. Possible contribution of prior hepatitis B virus infection to the development of hepatocellular carcinoma. J Gastroenterol Hepatol 2005;20:850-6. [PMID: 15946131 DOI: 10.1111/j.1440-1746.2005.03823.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
250 Yao FY, Kinkhabwala M, LaBerge JM, Bass NM, Brown R, Kerlan R, Venook A, Ascher NL, Emond JC, Roberts JP. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant. 2005;5:795-804. [PMID: 15760404 DOI: 10.1111/j.1600-6143.2005.00750.x] [Cited by in Crossref: 140] [Cited by in F6Publishing: 121] [Article Influence: 8.2] [Reference Citation Analysis]
251 A. Richard S; Department of Medicine, Princefield University, P. O. Box MA 128, Ho-Volta Region, Ghana West Africa. . AIMS Molecular Science 2018;5:183-241. [DOI: 10.3934/molsci.2018.4.183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
252 Di-Wen S, Pan GZ, Hao L, Zhang J, Xue QZ, Wang P, Yuan QZ. Improved antitumor activity of epirubicin-loaded CXCR4-targeted polymeric nanoparticles in liver cancers. Int J Pharm 2016;500:54-61. [PMID: 26748365 DOI: 10.1016/j.ijpharm.2015.12.066] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
253 Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. The Lancet 2003;362:1907-17. [DOI: 10.1016/s0140-6736(03)14964-1] [Cited by in Crossref: 3076] [Cited by in F6Publishing: 1294] [Article Influence: 161.9] [Reference Citation Analysis]
254 Mourra N, Arrive L, Paye F. An asymptomatic, radiographically undetected hepatocellular carcinoma that presented as a large retropancreatic mass. Clin Gastroenterol Hepatol 2009;7:e25-6. [PMID: 19249401 DOI: 10.1016/j.cgh.2008.10.016] [Reference Citation Analysis]
255 Toyama T, Hiramatsu N, Yakushijin T, Oze T, Nakanishi F, Yasumaru M, Mochizuki K, Kanto T, Takehara T, Kasahara A. A new prognostic system for hepatocellular carcinoma including recurrent cases: a study of 861 patients in a single institution. J Clin Gastroenterol. 2008;42:317-322. [PMID: 18223490 DOI: 10.1097/mcg.0b013e3180ebe790] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 0.1] [Reference Citation Analysis]
256 Huang WJ, Jeng YM, Lai HS, Fong IU, Sheu FY, Lai PL, Yuan RH. Expression of hypoxic marker carbonic anhydrase IX predicts poor prognosis in resectable hepatocellular carcinoma. PLoS One 2015;10:e0119181. [PMID: 25738958 DOI: 10.1371/journal.pone.0119181] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
257 Yang L, Zhang Z, Sun Y, Pang S, Yao Q, Lin P, Cheng J, Li J, Ding G, Hui L, Li Y, Li H. Integrative analysis reveals novel driver genes and molecular subclasses of hepatocellular carcinoma. Aging (Albany NY) 2020;12:23849-71. [PMID: 33221766 DOI: 10.18632/aging.104047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
258 Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, Wu Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Tsujinoue H, Masaki T, Fukui H. Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology 2004;39:1517-24. [PMID: 15185292 DOI: 10.1002/hep.20218] [Cited by in Crossref: 72] [Cited by in F6Publishing: 72] [Article Influence: 4.0] [Reference Citation Analysis]
259 Yamamoto T, Nagano H, Imai Y, Fukuda K, Matsumoto H, Kondo M, Ota H, Nakamura M, Wada H, Noda T, Damdinsuren B, Dono K, Umeshita K, Nakamori S, Sakon M, Wakasa K, Monden M. Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy. Int J Clin Oncol 2007;12:150-4. [PMID: 17443284 DOI: 10.1007/s10147-006-0630-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
260 Qin X, Zhang H, Zhou X, Wang C, Zhang H, Zhang X, Ye L. Proliferation and migration mediated by Dkk-1/Wnt/beta-catenin cascade in a model of hepatocellular carcinoma cells. Transl Res. 2007;150:281-294. [PMID: 17964517 DOI: 10.1016/j.trsl.2007.06.005] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 2.6] [Reference Citation Analysis]
261 Bialecki ES, Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB (Oxford). 2005;7:26-34. [PMID: 18333158 DOI: 10.1080/13651820410024049] [Cited by in Crossref: 132] [Cited by in F6Publishing: 125] [Article Influence: 11.0] [Reference Citation Analysis]
262 Amin MN, Siddiqui SA, Ibrahim M, Hakim ML, Ahammed MS, Kabir A, Sultana F. Inflammatory cytokines in the pathogenesis of cardiovascular disease and cancer. SAGE Open Med 2020;8:2050312120965752. [PMID: 33194199 DOI: 10.1177/2050312120965752] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
263 Zhang S, Li J, Wang X. NKD1 correlates with a poor prognosis and inhibits cell proliferation by inducing p53 expression in hepatocellular carcinoma. Tumour Biol 2016;37:14059-67. [PMID: 27507614 DOI: 10.1007/s13277-016-5173-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
264 Xu D, Liu X, Wu J, Wang Y, Zhou K, Chen W, Chen J, Chen C, Chen L. LncRNA WWOX-AS1 sponges miR-20b-5p in hepatocellular carcinoma and represses its progression by upregulating WWOX. Cancer Biol Ther 2020;21:927-36. [PMID: 32931356 DOI: 10.1080/15384047.2020.1806689] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
265 Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford). 2005;7:35-41. [PMID: 18333159 DOI: 10.1080/13651820410024058] [Cited by in Crossref: 153] [Cited by in F6Publishing: 147] [Article Influence: 12.8] [Reference Citation Analysis]
266 Shen Y, Bu L, Li R, Chen Z, Tian F, Lu N, Ge Q, Bai Y, Lu Z. Screening effective differential expression genes for hepatic carcinoma with metastasis in the peripheral blood mononuclear cells by RNA-seq. Oncotarget 2017;8:27976-89. [PMID: 28427195 DOI: 10.18632/oncotarget.15855] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
267 Shao L, Ye Q, Jia M. miR-130-3p Promotes MTX-Induced Immune Killing of Hepatocellular Carcinoma Cells by Targeting EPHB4. J Healthc Eng 2021;2021:4650794. [PMID: 34336153 DOI: 10.1155/2021/4650794] [Reference Citation Analysis]
268 Kuroda S, Tashiro H, Kobayashi T, Oshita A, Amano H, Ohdan H. Selection criteria for hepatectomy in patients with hepatocellular carcinoma classified as Child-Pugh class B. World J Surg. 2011;35:834-841. [PMID: 21190110 DOI: 10.1007/s00268-010-0929-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
269 Suk FM, Lien GS, Huang WJ, Chen CN, Lu SY, Yang YC, Yan MD, Liang YC. A Taiwanese Propolis Derivative Induces Apoptosis through Inducing Endoplasmic Reticular Stress and Activating Transcription Factor-3 in Human Hepatoma Cells. Evid Based Complement Alternat Med 2013;2013:658370. [PMID: 24222778 DOI: 10.1155/2013/658370] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
270 Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G. Current management strategy of hepatocellular carcinoma. World J Gastroenterol 2009; 15(26): 3210-3216 [PMID: 19598295 DOI: 10.3748/wjg.15.3210] [Cited by in CrossRef: 93] [Cited by in F6Publishing: 93] [Article Influence: 7.2] [Reference Citation Analysis]
271 Alexander ES, Wolf FJ, Machan JT, Charpentier KP, Beland MD, Iannuccilli JD, Haas RH, Dupuy DE. Microwave ablation of focal hepatic malignancies regardless of size: A 9-year retrospective study of 64 patients. Eur J Radiol 2015;84:1083-90. [PMID: 25818732 DOI: 10.1016/j.ejrad.2015.02.027] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
272 Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, Sun Y, Xuan SY. Association between HLA-DRB1 alleles polymorphism and hepatocellular carcinoma: a meta-analysis. BMC Gastroenterol. 2010;10:145. [PMID: 21172035 DOI: 10.1186/1471-230X-10-145] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
273 Dong LW, Yang GZ, Pan YF, Chen Y, Tan YX, Dai RY, Ren YB, Fu J, Wang HY. The oncoprotein p28GANK establishes a positive feedback loop in β-catenin signaling. Cell Res 2011;21:1248-61. [PMID: 21691299 DOI: 10.1038/cr.2011.103] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
274 Thiesen AL. Hepatocellular Carcinoma in Adults. In: Sergi CM, editor. Liver Cancer. Exon Publications; 2021. pp. 39-54. [DOI: 10.36255/exonpublications.livercancer.2021.ch2] [Reference Citation Analysis]
275 Schwartz M, D'amico F, Vitale A, Emre S, Cillo U. Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid? European Journal of Surgical Oncology (EJSO) 2008;34:256-62. [DOI: 10.1016/j.ejso.2007.07.208] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
276 Fuster J, Charco R, Llovet JM, Bruix J, García-Valdecasas JC. Liver transplantation in hepatocellular carcinoma. Transpl Int. 2005;18:278-282. [PMID: 15730486 DOI: 10.1111/j.1432-2277.2004.00046.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
277 Fukami Y, Kaneoka Y, Maeda A, Kumada T, Tanaka J, Akita T, Kubo S, Izumi N, Kadoya M, Sakamoto M, Nakashima O, Matsuyama Y, Kokudo T, Hasegawa K, Yamashita T, Kashiwabara K, Takayama T, Kokudo N, Kudo M;  Liver Cancer Study Group of Japan. Liver Resection for Multiple Hepatocellular Carcinomas: A Japanese Nationwide Survey. Ann Surg. 2020;272:145-154. [PMID: 30672806 DOI: 10.1097/sla.0000000000003192] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
278 Seleem MI, Gerges SS, Elkhouly A, El-Wakeel B, Hassany M. Laparoscopic Radiofrequency Thermal Ablation of Hepatocellular Carcinoma in Liver Cirrhosis Patients. Gastroenterology Res 2012;5:232-5. [PMID: 27785213 DOI: 10.4021/gr490w] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
279 Chen WH, Liao CW, Luo TY, Chang Y, Men LC, Hsieh YC. High performance liquid chromatography-tandem mass spectrometry method for ex vivo metabolic studies of a rhenium-labeled radiopharmaceutical for liver cancer. Eur J Mass Spectrom (Chichester) 2014;20:375-82. [PMID: 25707127 DOI: 10.1255/ejms.1288] [Reference Citation Analysis]
280 Scheurlen M, Brambs H, Gassel H. Hepatocellular Carcinoma. In: Scheppach W, Bresalier RS, Tytgat GNJ, editors. Gastrointestinal and Liver Tumors. Berlin: Springer Berlin Heidelberg; 2004. pp. 261-79. [DOI: 10.1007/978-3-642-18629-5_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
281 Colnot S, Decaens T, Niwa-Kawakita M, Godard C, Hamard G, Kahn A, Giovannini M, Perret C. Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci USA. 2004;101:17216-17221. [PMID: 15563600 DOI: 10.1073/pnas.0404761101] [Cited by in Crossref: 222] [Cited by in F6Publishing: 203] [Article Influence: 12.3] [Reference Citation Analysis]
282 Yang J, Tian Y, Zheng R, Li L, Qiu F. Endocannabinoid system and the expression of endogenous ceramides in human hepatocellular carcinoma. Oncol Lett 2019;18:1530-8. [PMID: 31423220 DOI: 10.3892/ol.2019.10399] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
283 Shigematsu S, Fukuda S, Nakayama H, Inoue H, Hiasa Y, Onji M, Higashiyama S. ZNF689 suppresses apoptosis of hepatocellular carcinoma cells through the down-regulation of Bcl-2 family members. Exp Cell Res. 2011;317:1851-1859. [PMID: 21624362 DOI: 10.1016/j.yexcr.2011.05.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
284 Li Z, Liu Y, Yan J, Zeng Q, Hu Y, Wang H, Li H, Li J, Yu Z. Circular RNA hsa_circ_0056836 functions an oncogenic gene in hepatocellular carcinoma through modulating miR-766-3p/FOSL2 axis. Aging (Albany NY) 2020;12:2485-97. [PMID: 32048611 DOI: 10.18632/aging.102756] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
285 Ravaioli M, Grazi GL, Ercolani G, Cescon M, Del Gaudio M, Zanello M, Ballardini G, Varotti G, Vetrone G, Tuci F. Liver allocation for hepatocellular carcinoma: a European Center policy in the pre-MELD era. Transplantation. 2006;81:525-530. [PMID: 16495798 DOI: 10.1097/01.tp.0000198741.39637.44] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
286 Zakrzewska KE, Samluk A, Wierzbicki M, Jaworski S, Kutwin M, Sawosz E, Chwalibog A, Pijanowska DG, Pluta KD. Analysis of the cytotoxicity of carbon-based nanoparticles, diamond and graphite, in human glioblastoma and hepatoma cell lines. PLoS One 2015;10:e0122579. [PMID: 25816103 DOI: 10.1371/journal.pone.0122579] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
287 Sala M, Varela M, Bruix J. Selection of candidates with HCC for transplantation in the MELD era. Liver Transpl. 2004;10:S4-S9. [PMID: 15382217 DOI: 10.1002/lt.20263] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
288 Yen Y, Changchien C, Wang J, Kee K, Hung C, Hu T, Lee C, Lin C, Wang C, Chen T, Huang Y, Lu S. A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients. Digestive and Liver Disease 2009;41:431-41. [DOI: 10.1016/j.dld.2008.11.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
289 Pinzani M, Rombouts K, Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol. 2005;42 Suppl:S22-S36. [PMID: 15777570 DOI: 10.1016/j.jhep.2004.12.008] [Cited by in Crossref: 163] [Cited by in F6Publishing: 147] [Article Influence: 9.1] [Reference Citation Analysis]
290 Jablonski EM, Mattocks MA, Sokolov E, Koniaris LG, Hughes FM, Fausto N, Pierce RH, McKillop IH. Decreased aquaporin expression leads to increased resistance to apoptosis in hepatocellular carcinoma. Cancer Lett. 2007;250:36-46. [PMID: 17084522 DOI: 10.1016/j.canlet.2006.09.013] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 5.4] [Reference Citation Analysis]
291 Di Bisceglie AM, Osmack P, Brunt EM. Chemoprevention of hepatocellular carcinoma: Use of tamoxifen in an animal model of hepatocarcinogenesis. Journal of Laboratory and Clinical Medicine 2005;145:134-8. [DOI: 10.1016/j.lab.2005.01.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
292 Ye Z, Houssein HS, Mahato RI. Bioconjugation of oligonucleotides for treating liver fibrosis. Oligonucleotides 2007;17:349-404. [PMID: 18154454 DOI: 10.1089/oli.2007.0097] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
293 Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol. 2005;42:218-224. [PMID: 15664247 DOI: 10.1016/j.jhep.2004.10.005] [Cited by in Crossref: 300] [Cited by in F6Publishing: 271] [Article Influence: 17.6] [Reference Citation Analysis]
294 Rajesh V, Perumal P. Chemopreventive and antioxidant activity by Smilax zeylanica leaf extract against N-nitrosodiethylamine induced hepatocarcinogenesis in wistar albino rats. Orient Pharm Exp Med 2014;14:111-26. [DOI: 10.1007/s13596-013-0125-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
295 Ozkan H, Erdal H, Koçak E, Tutkak H, Karaeren Z, Yakut M, Köklü S. Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma. J Clin Lab Anal. 2011;25:350-353. [PMID: 21919070 DOI: 10.1002/jcla.20484] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
296 Zucman-Rossi J, Benhamouche S, Godard C, Boyault S, Grimber G, Balabaud C, Cunha AS, Bioulac-Sage P, Perret C. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene. 2007;26:774-780. [PMID: 16964294 DOI: 10.1038/sj.onc.1209824] [Cited by in Crossref: 161] [Cited by in F6Publishing: 149] [Article Influence: 10.1] [Reference Citation Analysis]
297 Simon CJ, Dupuy DE, Iannitti DA, Lu DS, Yu NC, Aswad BI, Busuttil RW, Lassman C. Intraoperative triple antenna hepatic microwave ablation. AJR Am J Roentgenol. 2006;187:W333-W340. [PMID: 16985103 DOI: 10.2214/ajr.05.0804] [Cited by in Crossref: 71] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
298 Khan AR, Wei X, Xu X. Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides. J Hepatocell Carcinoma 2021;8:1089-115. [PMID: 34522691 DOI: 10.2147/JHC.S318070] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
299 Erichsen R, Jepsen P, Jacobsen J, Nørgaard M, Vilstrup H, Sørensen HT. Time trends in incidence and prognosis of primary liver cancer and liver metastases of unknown origin in a Danish region, 1985–2004: . European Journal of Gastroenterology & Hepatology 2008;20:104-10. [DOI: 10.1097/meg.0b013e3282f17517] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
300 Arunraj TR, Sanoj Rejinold N, Ashwin Kumar N, Jayakumar R. Bio-responsive chitin-poly(L-lactic acid) composite nanogels for liver cancer. Colloids Surf B Biointerfaces 2014;113:394-402. [PMID: 24129331 DOI: 10.1016/j.colsurfb.2013.09.023] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
301 Hung IF, Wong DK, Poon RT, Fong DY, Chui AH, Seto WK, Fung JY, Chan AC, Yuen JC, Tiu R, Choi O, Lai CL, Yuen MF. Risk Factors and Post-Resection Independent Predictive Score for the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma. PLoS One 2016;11:e0148493. [PMID: 26901762 DOI: 10.1371/journal.pone.0148493] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
302 Peng X, Lin G, Zeng Y, Lei Z, Liu G. Mesoporous Silica Nanoparticle-Based Imaging Agents for Hepatocellular Carcinoma Detection. Front Bioeng Biotechnol 2021;9:749381. [PMID: 34869261 DOI: 10.3389/fbioe.2021.749381] [Reference Citation Analysis]
303 Kaibori M, Saito T, Matsui Y, Uchida Y, Ishizaki M, Kamiyama Y. A review of the prognostic factors in patients with recurrence after liver resection for hepatocellular carcinoma. Am J Surg 2007;193:431-7. [PMID: 17368283 DOI: 10.1016/j.amjsurg.2006.06.041] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
304 Kaibori M, Ha-kawa SK, Ishizaki M, Matsui K, Saito T, Kwon A, Kamiyama Y. HA/GSA-Rmax Ratio as a Predictor of Postoperative Liver Failure. World J Surg 2008;32:2410-8. [DOI: 10.1007/s00268-008-9725-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
305 Jo M, Nishikawa T, Nakajima T, Okada Y, Yamaguchi K, Mitsuyoshi H, Yasui K, Minami M, Iwai M, Kagawa K. Oxidative stress is closely associated with tumor angiogenesis of hepatocellular carcinoma. J Gastroenterol. 2011;46:809-821. [PMID: 21452000 DOI: 10.1007/s00535-011-0392-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
306 Lempinen M, Lyytinen I, Nordin A, Tervahartiala T, Mäkisalo H, Sorsa T, Isoniemi H. Prognostic value of serum MMP-8, -9 and TIMP-1 in patients with hepatocellular carcinoma. Ann Med 2013;45:482-7. [PMID: 23962148 DOI: 10.3109/07853890.2013.823779] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
307 Lin YW, Shih YL, Lien GS, Suk FM, Hsieh CB, Yan MD. Promoter methylation of SFRP3 is frequent in hepatocellular carcinoma. Dis Markers 2014;2014:351863. [PMID: 24591760 DOI: 10.1155/2014/351863] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
308 Kung JW, Currie IS, Forbes SJ, Ross JA. Liver development, regeneration, and carcinogenesis. J Biomed Biotechnol 2010;2010:984248. [PMID: 20169172 DOI: 10.1155/2010/984248] [Cited by in Crossref: 32] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
309 Meyerovich G, Goykhman Y, Nakache R, Nachmany I, Lahat G, Shibolet O, Menachem Y, Katchman H, Wolf I, Geva R, Klausner JM, Lubezky N. Resection vs Transplant Listing for Hepatocellular Carcinoma: An Intention-to-Treat Analysis. Transplant Proc 2019;51:1867-73. [PMID: 31399171 DOI: 10.1016/j.transproceed.2019.02.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
310 Hanazawa T, Fukami Y, Osawa T, Kurahashi S, Matsumura T, Saito T, Komatsu S, Kaneko K, Tsuzuki T, Sano T. A case of resected hepatocellular carcinoma with gallbladder metastasis. Surg Case Rep 2021;7:145. [PMID: 34138407 DOI: 10.1186/s40792-021-01222-7] [Reference Citation Analysis]
311 Motola-kuba D, Zamora-valdés D, Uribe M, Méndez-sánchez N. Hepatocellular carcinoma. An overview. Annals of Hepatology 2006;5:16-24. [DOI: 10.1016/s1665-2681(19)32034-4] [Cited by in Crossref: 88] [Article Influence: 5.5] [Reference Citation Analysis]
312 Yu Y, Zhang Y, Hu J, Zhang H, Wang S, Han F, Yue L, Qu Y, Zhang Y, Liang H, Nie H, Li Y. MARVELD1 inhibited cell proliferation and enhance chemosensitivity via increasing expression of p53 and p16 in hepatocellular carcinoma. Cancer Sci 2012;103:716-22. [PMID: 22320884 DOI: 10.1111/j.1349-7006.2012.02220.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
313 Chang CJ, Hou MC, Tseng HS, Liao WC, Lin HC, Lee SD. Bleeding gastric ulcer after prophylactic coiling of transarterial chemoembolization. J Clin Gastroenterol 2010;44:588-91. [PMID: 20453659 DOI: 10.1097/MCG.0b013e3181d9eff3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
314 Befeler AS, Hayashi PH, Di Bisceglie AM. Liver transplantation for hepatocellular carcinoma. Gastroenterology. 2005;128:1752-1764. [PMID: 15887162 DOI: 10.1053/j.gastro.2005.03.033] [Cited by in Crossref: 93] [Cited by in F6Publishing: 86] [Article Influence: 5.5] [Reference Citation Analysis]
315 Kowsalya R, Kaliaperumal J, Vaishnavi M, Namasivayam E. Anticancer activity of Cynodon dactylon L. root extract against diethyl nitrosamine induced hepatic carcinoma. South Asian J Cancer 2015;4:83-7. [PMID: 25992348 DOI: 10.4103/2278-330X.155691] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
316 Zou LQ, Chen J, Pan L, Jiang JZ, Xing W. Comparison of magnetic resonance elastography and diffusion-weighted imaging for staging hepatic fibrosis. Chin Med J (Engl). 2015;128:620-625. [PMID: 25698193 DOI: 10.4103/0366-6999.151659] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
317 Iannitti DA, Martin RC, Simon CJ, Hope WW, Newcomb WL, McMasters KM, Dupuy D. Hepatic tumor ablation with clustered microwave antennae: the US Phase II trial. HPB (Oxford). 2007;9:120-124. [PMID: 18333126 DOI: 10.1080/13651820701222677] [Cited by in Crossref: 98] [Cited by in F6Publishing: 83] [Article Influence: 8.2] [Reference Citation Analysis]
318 Corona-Villalobos CP, Halappa VG, Bonekamp S, Eng J, Reyes D, Cosgrove D, Rastegar N, Pan L, Pawlik TM, Kamel IR. Functional magnetic resonance imaging response of targeted tumor burden and its impact on survival in patients with hepatocellular carcinoma. Invest Radiol. 2015;50:283-289. [PMID: 25396692 DOI: 10.1097/rli.0000000000000112] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
319 Wang BW, Mok KT, Liu SI, Chou NH, Tsai CC, Chen IS, Yeh MH, Chen YC. Is hepatectomy beneficial in the treatment of multinodular hepatocellular carcinoma? J Formos Med Assoc. 2008;107:616-626. [PMID: 18678545 DOI: 10.1016/s0929-6646(08)60179-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
320 Shin SK, Kim YS, Shim YS, Choi SJ, Park SH, Jung DH, Kwon OS, Choi DJ, Kim JH. Peritumoral decreased uptake area of gadoxetic acid enhanced magnetic resonance imaging and tumor recurrence after surgical resection in hepatocellular carcinoma: A STROBE-compliant article. Medicine (Baltimore) 2017;96:e7761. [PMID: 28816953 DOI: 10.1097/MD.0000000000007761] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
321 Hung IF, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol. 2008;103:1663-1673. [PMID: 18616655 DOI: 10.1111/j.1572-0241.2008.01872.x] [Cited by in Crossref: 122] [Cited by in F6Publishing: 124] [Article Influence: 8.7] [Reference Citation Analysis]
322 Xu H, Gong G, Wei H, Chen L, Chen J, Lu J, Liu T, Zhu J, Yin Y. Feasibility and potential benefits of defining the internal gross tumor volume of hepatocellular carcinoma using contrast-enhanced 4D CT images obtained by deformable registration. Radiat Oncol 2014;9:221. [PMID: 25319176 DOI: 10.1186/s13014-014-0221-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
323 D'Alessandro LA, Meyer R, Klingmüller U. Hepatocellular carcinoma: a systems biology perspective. Front Physiol 2013;4:28. [PMID: 23444340 DOI: 10.3389/fphys.2013.00028] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
324 Che Y, Zhang DY, Ye F, Wu B, Jiang B. Combination of flavopiridol and embelin effectively inhibit cell growth in hepatocellular carcinoma depending on regulatory relationship between CDK6 and XIAP. Med Chem Res 2012;21:3369-75. [DOI: 10.1007/s00044-011-9867-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
325 Marrero JA. Hepatocellular carcinoma: . Current Opinion in Gastroenterology 2003;19:243-9. [DOI: 10.1097/00001574-200305000-00007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
326 Li ZL, Yu JJ, Guo JW, Sui CJ, Dai BH, Zhang WG, Chen TH, Li C, Gu WM, Zhou YH, Wang H, Zhang YM, Mao XH, Pawlik TM, Wang MD, Liang L, Wu H, Lau WY, Wu MC, Shen F, Yang T. Liver resection is justified for multinodular hepatocellular carcinoma in selected patients with cirrhosis: A multicenter analysis of 1,066 patients. Eur J Surg Oncol 2019;45:800-7. [PMID: 30594407 DOI: 10.1016/j.ejso.2018.12.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
327 Brunetti A, Carnimeo L, Trotta GF, Bevilacqua V. Computer-assisted frameworks for classification of liver, breast and blood neoplasias via neural networks: A survey based on medical images. Neurocomputing 2019;335:274-98. [DOI: 10.1016/j.neucom.2018.06.080] [Cited by in Crossref: 27] [Cited by in F6Publishing: 1] [Article Influence: 9.0] [Reference Citation Analysis]
328 Cenderello G, Pontali E, Cassola G, Torresin A. Could anti-HCV treatment prevent recurrence of hepatocellular carcinoma in HIV-infected patients? Two case reports. Infection 2013;41:199-202. [PMID: 23065464 DOI: 10.1007/s15010-012-0353-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
329 Liu JG, Wang YJ, Du Z. Radiofrequency ablation in the treatment of small hepatocellular carcinoma: A meta analysis. World J Gastroenterol 2010; 16(27): 3450-3456 [PMID: 20632451 DOI: 10.3748/wjg.v16.i27.3450] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
330 Bao L, Chandra PK, Moroz K, Zhang X, Thung SN, Wu T, Dash S. Impaired autophagy response in human hepatocellular carcinoma. Exp Mol Pathol 2014;96:149-54. [PMID: 24369267 DOI: 10.1016/j.yexmp.2013.12.002] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 5.2] [Reference Citation Analysis]
331 Wolfe A, Thomas A, Edwards G, Jaseja R, Guo GL, Apte U. Increased activation of the Wnt/β-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice. J Pharmacol Exp Ther. 2011;338:12-21. [PMID: 21430080 DOI: 10.1124/jpet.111.179390] [Cited by in Crossref: 83] [Cited by in F6Publishing: 88] [Article Influence: 7.5] [Reference Citation Analysis]
332 Yan S, Tang Z, Chen K, Liu Y, Yu G, Chen Q, Dang H, Chen F, Ling J, Zhu L, Huang A, Tang H. Long noncoding RNA MIR31HG inhibits hepatocellular carcinoma proliferation and metastasis by sponging microRNA-575 to modulate ST7L expression. J Exp Clin Cancer Res 2018;37:214. [PMID: 30176933 DOI: 10.1186/s13046-018-0853-9] [Cited by in Crossref: 52] [Cited by in F6Publishing: 59] [Article Influence: 13.0] [Reference Citation Analysis]
333 Ruzzenente A, Valdegamberi A, Campagnaro T, Conci S, Pachera S, Iacono C, Guglielmi A. Hepatocellular carcinoma in cirrhotic patients with portal hypertension: Is liver resection always contraindicated? World J Gastroenterol 2011; 17(46): 5083-5088 [PMID: 22171142 DOI: 10.3748/wjg.v17.i46.5083] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
334 Park KW, Park JW, Choi JI, Kim TH, Kim SH, Park HS, Lee WJ, Park SJ, Hong EK, Kim CM. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol 2008;23:467-73. [PMID: 17764529 DOI: 10.1111/j.1440-1746.2007.05112.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 85] [Article Influence: 5.5] [Reference Citation Analysis]
335 Lin ZZ, Hsu HC, Hsu CH, Yeh PY, Huang CY, Huang YF, Chen TJ, Kuo SH, Hsu C, Hu FC, Jeng YM, Chung Y, Cheng AL. The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma. J Hepatol 2009;50:518-27. [PMID: 19155085 DOI: 10.1016/j.jhep.2008.10.022] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
336 Lien HC, Jeng YM, Jhuang YL, Yuan RH. Increased Trimethylation of histone H3K36 associates with biliary differentiation and predicts poor prognosis in resectable hepatocellular carcinoma. PLoS One 2018;13:e0206261. [PMID: 30356299 DOI: 10.1371/journal.pone.0206261] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
337 Toyoda H, Kumada T, Kaneoka Y, Maeda A. Amino Acid Substitutions in the Hepatitis C Virus Core Region Are Associated With Postoperative Recurrence and Survival of Patients With HCV Genotype 1b-Associated Hepatocellular Carcinoma. Annals of Surgery 2011;254:326-32. [DOI: 10.1097/sla.0b013e3182263b8e] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
338 Blum HE. Treatment of hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology 2005;19:129-45. [DOI: 10.1016/j.bpg.2004.11.008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
339 Zhou Y, Yu Q, Qin X, Bhavsar D, Yang L, Chen Q, Zheng W, Chen L, Liu J. Improving the Anticancer Efficacy of Laminin Receptor-Specific Therapeutic Ruthenium Nanoparticles (RuBB-Loaded EGCG-RuNPs) via ROS-Dependent Apoptosis in SMMC-7721 Cells. ACS Appl Mater Interfaces 2016;8:15000-12. [PMID: 26018505 DOI: 10.1021/acsami.5b02261] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
340 Thng Y, Tan JK, Shridhar IG, Chang SK, Madhavan K, Kow AW. Outcomes of resection of giant hepatocellular carcinoma in a tertiary institution: does size matter? HPB (Oxford) 2015;17:988-93. [PMID: 26334002 DOI: 10.1111/hpb.12479] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
341 Henderson JM, Sherman M, Tavill A, Abecassis M, Chejfec G, Gramlich T. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. HPB (Oxford). 2003;5:243-250. [PMID: 18332995 DOI: 10.1080/13651820310015833] [Cited by in Crossref: 85] [Cited by in F6Publishing: 82] [Article Influence: 7.1] [Reference Citation Analysis]
342 Ding HF, Zhang XF, Bagante F, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Lv Y, Pawlik TM. Prediction of tumor recurrence by α-fetoprotein model after curative resection for hepatocellular carcinoma. Eur J Surg Oncol 2021;47:660-6. [PMID: 33082065 DOI: 10.1016/j.ejso.2020.10.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
343 Obara K, Matsumoto N, Okamoto M, Kobayashi M, Ikeda H, Takahashi H, Katakura Y, Matsunaga K, Ishii T, Okuse C. Insufficient radiofrequency ablation therapy may induce further malignant transformation of hepatocellular carcinoma. Hepatol Int. 2008;2:116-123. [PMID: 19669287 DOI: 10.1007/s12072-007-9040-3] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 2.9] [Reference Citation Analysis]
344 Brunt EM, Walsh SN, Hayashi PH, Labundy J, Di Bisceglie AM. Hepatocyte senescence in end-stage chronic liver disease: a study of cyclin-dependent kinase inhibitor p21 in liver biopsies as a marker for progression to hepatocellular carcinoma. Liver Int. 2007;27:662-671. [PMID: 17498252 DOI: 10.1111/j.1478-3231.2007.01470.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
345 Cazauran JB, Pâris L, Rousset P, Mercier F, Kepenekian V, Viste A, Passot G. Anatomy of the Right Anterior Sector of the Liver and Its Clinical Implications in Surgery. J Gastrointest Surg 2018;22:1819-31. [PMID: 29916108 DOI: 10.1007/s11605-018-3831-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
346 Del Gaudio M, Ercolani G, Ravaioli M, Cescon M, Lauro A, Vivarelli M, Zanello M, Cucchetti A, Vetrone G, Tuci F. Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience. Am J Transplant. 2008;8:1177-1185. [PMID: 18444925 DOI: 10.1111/j.1600-6143.2008.02229.x] [Cited by in Crossref: 114] [Cited by in F6Publishing: 118] [Article Influence: 8.1] [Reference Citation Analysis]
347 Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Niinomi T, Ito T. Oral supplementation with branched-chain amino acid granules prevents hepatocarcinogenesis in patients with hepatitis C-related cirrhosis: A propensity score analysis. Hepatol Res. 2013;Epub ahead of print. [PMID: 23607436 DOI: 10.1111/hepr.12120] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
348 Mohamed FZ, Hussein YM, El-deen IM, Sabea MS. Cyclooxygenase-2 single-nucleotide polymorphisms and hepatocellular carcinoma in Egypt. Mol Biol Rep 2014;41:1461-8. [DOI: 10.1007/s11033-013-2991-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
349 Chang C, Chen Y, Huang K, Cheng H, Chan S, Tai K, Hwang L. Combined GM-CSF and IL-12 gene therapy synergistically suppresses the growth of orthotopic liver tumors. Hepatology 2007;45:746-54. [DOI: 10.1002/hep.21560] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 3.1] [Reference Citation Analysis]
350 Couto OFM, Dvorchik I, Carr BI. Causes of Death in Patients with Unresectable Hepatocellular Carcinoma. Dig Dis Sci 2007;52:3285-9. [DOI: 10.1007/s10620-007-9750-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
351 Liu HH, Fang Y, Wang JW, Yuan XD, Fan YC, Gao S, Han LY, Wang K. Hypomethylation of the cyclin D1 promoter in hepatitis B virus-associated hepatocellular carcinoma. Medicine (Baltimore) 2020;99:e20326. [PMID: 32443384 DOI: 10.1097/MD.0000000000020326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
352 Yao FY. Liver transplantation for hepatocellular carcinoma: The hepatitis C quandary. Liver Transpl 2007;13:783-5. [DOI: 10.1002/lt.21062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
353 Dong J, Xu X, Ke M, Xiang J, Liu W, Liu X, Wang B, Zhang X, Lv Y. The FIB-4 score predicts postoperative short-term outcomes of hepatocellular carcinoma fulfilling the milan criteria. European Journal of Surgical Oncology (EJSO) 2016;42:722-7. [DOI: 10.1016/j.ejso.2016.02.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
354 Shao YY, Huang CC, Liang PC, Lin ZZ. Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma. Asia Pac J Clin Oncol 2010;6:80-8. [PMID: 20565419 DOI: 10.1111/j.1743-7563.2010.01287.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
355 Moral A, Magarzo J. Marcadores tumorales serológicos en cirugía hepatobiliopancreática. Cirugía Española 2004;76:276-83. [DOI: 10.1016/s0009-739x(04)72378-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
356 Ramadan RA, Madkour MA, El-nagarr MM, Abourawash SN. Serum clusterin as a marker for diagnosing hepatocellular carcinoma. Alexandria Journal of Medicine 2014;50:227-34. [DOI: 10.1016/j.ajme.2014.05.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
357 Tian L, Wang Y, Xu D, Gui J, Jia X, Tong H, Wen X, Dong Z, Tian Y. Serological AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases. Int J Cancer. 2011;129:1923-1931. [PMID: 21140449 DOI: 10.1002/ijc.25838] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 5.1] [Reference Citation Analysis]
358 Naar L, Hatzaras I. Liver Resection for Hepatocellular Carcinoma and the Barcelona Clinic Liver Cancer Criteria: Is It Time to Push the Limits? Ann Surg Oncol 2020;27:2122-4. [PMID: 32297086 DOI: 10.1245/s10434-020-08459-w] [Reference Citation Analysis]
359 Chen T, Chang T, Huang P, Tsai M, Lin L, Liu C, Ho K, Siauw C, Chao P, Tung J. Management and patient survival in hepatocellular carcinoma: Does the physician's level of experience matter? Journal of Gastroenterology and Hepatology 2008;23:e179-88. [DOI: 10.1111/j.1440-1746.2008.05341.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
360 Lin W, Luo T, Tsai S, Kao C, Tang I, Huang P. A comparison of Re-188-MN-16ET-lipiodol and transcatheter arterial chemoembolization in the treatment of hepatoma: An animal study. Nuclear Medicine and Biology 2013;40:437-41. [DOI: 10.1016/j.nucmedbio.2012.11.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
361 Moran DM, Mattocks MA, Cahill PA, Koniaris LG, McKillop IH. Interleukin-6 mediates G(0)/G(1) growth arrest in hepatocellular carcinoma through a STAT 3-dependent pathway. J Surg Res 2008;147:23-33. [PMID: 17574577 DOI: 10.1016/j.jss.2007.04.022] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
362 Jazieh KA, Arabi M, Khankan AA. Transarterial therapy: an evolving treatment modality of hepatocellular carcinoma. Saudi J Gastroenterol 2014;20:333-41. [PMID: 25434313 DOI: 10.4103/1319-3767.145315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
363 Reginelli A, Vanzulli A, Sgrazzutti C, Caschera L, Serra N, Raucci A, Urraro F, Cappabianca S. Vascular microinvasion from hepatocellular carcinoma: CT findings and pathologic correlation for the best therapeutic strategies. Med Oncol 2017;34:93. [PMID: 28401484 DOI: 10.1007/s12032-017-0949-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
364 Yamanaka J, Saito S, Fujimoto J. Impact of preoperative planning using virtual segmental volumetry on liver resection for hepatocellular carcinoma. World J Surg. 2007;31:1249-1255. [PMID: 17440774 DOI: 10.1007/s00268-007-9020-8] [Cited by in Crossref: 88] [Cited by in F6Publishing: 73] [Article Influence: 5.9] [Reference Citation Analysis]
365 Morihara D, Iwata K, Hanano T, Kunimoto H, Kuno S, Fukunaga A, Yotsumoto K, Takata K, Tanaka T, Sakurai K, Iwashita H, Ueda S, Hirano G, Yokoyama K, Nakane H, Nishizawa S, Yoshikane M, Anan A, Takeyama Y, Kakumitsu S, Kitamura Y, Sakamoto M, Irie M, Shakado S, Sohda T, Watanabe H, Sakisaka S. Late-evening snack with branched-chain amino acids improves liver function after radiofrequency ablation for hepatocellular carcinoma: LES with BCAA improves liver function. Hepatology Research 2012;42:658-67. [DOI: 10.1111/j.1872-034x.2012.00969.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
366 Bruix J, Llovet JM. Hepatitis B virus and hepatocellular carcinoma. J Hepatol 2003;39 Suppl 1:S59-63. [PMID: 14708679 DOI: 10.1016/s0168-8278(03)00140-5] [Cited by in Crossref: 70] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
367 Helmberger T, Dogan S, Straub G, Schrader A, Jüngst C, Reiser M, Waggershauser T, Jakobs T, Hoffmann R, Löhe F, Graeb C, Rau H, Schauer R, Jauch K, Caselmann WH, Göke B, Jüngst D. Liver Resection or Combined Chemoembolization and Radiofrequency Ablation Improve Survival in Patients with Hepatocellular Carcinoma. Digestion 2007;75:104-12. [DOI: 10.1159/000104730] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
368 Gharib AM, Thomasson D, Li KC. Molecular imaging of hepatocellular carcinoma. Gastroenterology 2004;127:S153-8. [DOI: 10.1053/j.gastro.2004.09.029] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
369 Myung SJ, Yoon J, Yu SJ. STAT3 & Cytochrome P450 2C9: A novel signaling pathway in liver cancer stem cells. Biomedicine & Pharmacotherapy 2012;66:612-6. [DOI: 10.1016/j.biopha.2012.08.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
370 Schölmerich J, Schacherer D. Diagnostic biopsy for hepatocellular carcinoma in cirrhosis: useful, necessary, dangerous, or academic sport? Gut 2004;53:1224-6. [PMID: 15306574 DOI: 10.1136/gut.2004.040816] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
371 Jiang H, Meng Q, Tan H, Pan S, Sun B, Xu R, Sun X. Antiangiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas. Int J Cancer. 2007;121:416-424. [PMID: 17330237 DOI: 10.1002/ijc.22655] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 2.5] [Reference Citation Analysis]
372 Choi BO, Choi IB, Jang HS, Kang YN, Jang JS, Bae SH, Yoon SK, Chai GY, Kang KM. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer. 2008;8:351. [PMID: 19038025 DOI: 10.1186/1471-2407-8-351] [Cited by in Crossref: 99] [Cited by in F6Publishing: 91] [Article Influence: 7.1] [Reference Citation Analysis]
373 Chen H, Zhang Y, Li S, Li N, Chen Y, Zhang B, Qu C, Ding H, Huang J, Dai M. Direct comparison of five serum biomarkers in early diagnosis of hepatocellular carcinoma. Cancer Manag Res 2018;10:1947-58. [PMID: 30022853 DOI: 10.2147/CMAR.S167036] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
374 Tse LY, Sun X, Jiang H, Dong X, Fung PW, Farzaneh F, Xu R. Adeno-associated virus-mediated expression of kallistatin suppresses local and remote hepatocellular carcinomas. J Gene Med. 2008;10:508-517. [PMID: 18338836 DOI: 10.1002/jgm.1180] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
375 Wang Z, Yang G, Nie P, Fu J, Wang X, Liu D. Dynamical observation on biological progression of VX2 liver tumors to identify the optimal time for intervention in animal models. PLoS One 2013;8:e74327. [PMID: 23977399 DOI: 10.1371/journal.pone.0074327] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
376 Spangenberg HC, Thimme R, Blum HE. Evolving therapies in the treatment of hepatocellular carcinoma. Biologics 2008;2:453-62. [PMID: 19707376 DOI: 10.2147/btt.s3254] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
377 Nakamura M, Nagano H, Sakon M, Yamamoto T, Ota H, Wada H, Damdinsuren B, Noda T, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Nakamori S, Dono K, Monden M. Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro. J Hepatol 2007;46:77-88. [PMID: 17045692 DOI: 10.1016/j.jhep.2006.07.032] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 3.1] [Reference Citation Analysis]